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Abstract 
I studied the capabilities of the two DNA lesions 8-oxo-guanine and cisplatin intrastrand 
crosslinked 1,2-d(GpG) or Pt-GG to cause mutations in mammalian cells. Using isogenic cell 
lines generated from mice with selective gene knockouts of distinct DNA polymerases as 
models, I deduced the biological functions of the translesion DNA polymerases Pol eta, Pol 
kappa, Pol iota, Rev1 and Rev3L on bypassing each of the lesions 8-oxo-G and Pt-GG. My 
study takes advantage of the Next Generation Sequencing (NGS) technology to determine 
mutagenic effects of the DNA lesions in vivo and effects of translesion DNA polymerases on 
bypassing the lesions. Through adapting a translesion synthesis (TLS) assay into a high-
throughput TLS assay which uses NGS, I eliminated steps in the traditional TLS assay that 
involves E. coli. My study reveals that 8-oxo-guanine caused a high frequency of C->A 
substitutions, and that significantly, Pol eta correctly bypassed 8-oxo-G in cells. The high 
mutation rate of 8-oxo-G underlines the importance of DNA repair to remove this lesion 
before it is replicated. By contrast, Pt-GG caused very few mutations in vivo: the mutation 
rate of Pt-GG was only two times the background error rate in my experiment. The five 
translesion DNA polymerases studied bypassed Pt-GG in an error-prone manner; 
specifically, Rev3L and Rev1 DNA polymerases can each bypass the lesion and Pol iota 
might share the function of Pol kappa or enhance that of Pol eta to bypass the lesion. Since 
Pt-GG does not appear to block DNA replication more than 8-oxo-G in mammalian cells, the 
cytotoxicity of the drug cisplatin that produces the cisplatin-DNA adduct is likely attributed 
to other causes, such as inter-strand cisplatin-DNA adducts that are more potent for stalling 
DNA replication.  
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Preface 
This dissertation is original, unpublished, independent work by the author, L. Guo, with 
funding and support provided by Dr. Ling. All the figures except Figures 2 and 3 are 
produced by the author.  
Concept formation of this project was initiated by Dr. Ling. To the author’s knowledge, the 
concept was, at various times, consulted with Dr. Edgell, Dr. Gloor, and Guangxing Xing. 
The author was involved in concept formation, planning and execution of the project.  
This work relies on a translesion synthesis assay that requires construction of double stranded 
gap plasmids. Even though the method of constructing the plasmids has been reported, when 
performing actual experiments the author used her ingenuity to solve several major problems, 
including gel purification, electro-elution, desalting DNA samples and scaling down 
transfection experiments. Although the traditional TLS assay described herein is similar in 
principal to what has been published by others, it may not be apparent from reading the thesis 
that the actual work is different in many aspects from those experiments carried out by 
others. The author in her own ways produced pure and highly transfectable gap plasmids that 
is an absolute requirement for obtaining high quality data. This should be noted as one of the 
achievements of the thesis project.  
The author is particularly interested in mutagenesis as a phenomenon of the living cell and as 
a random event that disturbs, makes disorder and creates variation in DNA sequence. Once a 
mutation has come to be through translesion synthesis, even if the initial effect is 
imperceptible, the mutation will not be erased but continue to develop and be influenced by 
the living condition of the cell and its environment. A mutation produced by DNA lesion is 
not merely a substitution of DNA bases, but is always a reflection of what is outside of the 
cell. From quantitative results presented in the thesis, the author became interested in 
thinking qualitatively about changes or other mutations brought by those produced from 
translesion synthesis in the cells. The author found Chaos theory an attractive model (but 
unfortunately, it was not defensible) to explain the nonlinear dynamics of mutations in 
relation to qualitative changes that occur in the cancer cell.   
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Chapter 1  
1 Introduction 
 
1.1 Y-family DNA polymerases are prone to making mutations 
Information encoded by genomic DNA is not static. The biological content of the genome 
adapts to the environment and is shaped by outside forces over time. One way genomic 
DNA sequences are changed is from chemical modifications of nucleotides. Y-family 
DNA polymerases bypass modified nucleotides or DNA lesions in a process called 
translesion synthesis (TLS) (Yang and Woodgate, 2007; Sale et al., 2012). Compared to 
DNA polymerases that accurately copy the whole genome, Y-family polymerases are 
prone to making mutations (Ohmori et al., 2001).  
Mutation is a natural phenomenon and a driving force of evolution. One way that 
mutations can arise is when DNA polymerases bypass lesions that block normal DNA 
replication. A stalled replication fork if not rescued by translesion DNA polymerases 
would fall apart—proteins of the replication machinery disassemble and a double 
stranded break forms. It is generally accepted that Y-family polymerases maintain 
genome stability by allowing DNA replication to continue despite DNA lesions that are 
ubiquitously present. This way, translesion synthesis ensures the cell’s survival and 
tolerates DNA damage; on the other hand, it increases the likelihood that the base 
inserted opposite to the DNA lesion would be changed.  
Translesion synthesis is one of the ways whereby DNA mutations occur. It's a major 
source of point mutation that involves change in the nucleotide opposite to the DNA 
lesion. Spontaneous mutations without facilitation of DNA lesions are rare but can arise 
in cells. At the gene level, these mutations are base substitution, insertion and deletion of 
one or several nucleotides given rise to by replication errors and spontaneous loss of 
DNA bases. There are also copy number DNA mutations such as expansion of 
trinucleotide DNA repeats exemplified in a genetic disease called fragile X syndrome, 
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whereby thousands of nucleotides were duplicated from CGG repeats. DNA mutations 
that affect production and folding of proteins are deleterious and could lead to increased 
susceptibility to illness and disease.  
 
 
Figure 1. Possible outcomes for when DNA replication is stalled by a DNA lesion in 
the template  
When DNA replication is stalled by a DNA lesion (indicated by the red circle), the cell 
can use the damage tolerance pathway to bypass the lesion (case 1). This involves two 
polymerase-switching events whereby in the first event, a replicative DNA polymerase is 
replaced by a translesion DNA polymerase which inserts a nucleotide across from the 
lesion, and in the second event, the replicative DNA polymerase is recruited back to 
continue normal DNA replication. Alternatively, the DNA replication machinery can skip 
the DNA lesion in what is called the damage avoidance pathway (cases 2 and 3) whereby 
the replicative DNA polymerase reinitiates DNA replication downstream from the lesion, 
leaving a small single stranded gap (Jansen, 2006). This gap is filled by translesion DNA 
polymerases later in the S or G2 phase of cell cycle (Daigaku et al., 2010; Karras and 
Jentsch, 2010; Elvers et al., 2011), and the nucleotide incorporated opposite to the lesion 
could either form the correct or mismatched base pair with the lesion (case 2). The single 
stranded gap can also be repaired by homologous recombination mediated by template 
switching (case 3). In this scenario, the DNA segment containing the lesion is not used as 
a template for DNA replication, thus the mutagenic effect of the DNA lesion is 
completely avoided. Failing the damage tolerance and the damage avoidance measures, a 
stalled DNA replication fork can be nicked by a single stranded endonuclease to form a 
double stranded break (case 4) whereupon DNA replication is terminated. 
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Translesion synthesis is a major source of point mutations or variations in the genome. 
These variations—if they are not strongly deleterious, are passed on for as long as a cell’s 
lineage is kept alive, without causing harmful effects to daughter cells. The purpose of 
studying translesion synthesis is to look at the initial conditions that perturb the genome. 
Similar to the butterfly effect (Lorenz, 1963; Lorenz, E.N., 1972), small and random 
changes that are regarded as errors or noises in the genome can have a remarkable effect 
on determining the cell’s fate. There is an element of chance and randomness in what 
shapes and what continues to shape the human genome. While the rate of mutation is 
tightly controlled in normal cells, a high rate of mutation is characteristic of tumor cells 
(Jackson and Loeb, 1998). Accumulation of point mutations increases the risk of 
developing cancer, especially if it is accompanied by defects in the cell’s DNA repair and 
cell cycle control mechanisms (Hartwell and Kastan, 1994; Lodish et al., 2000). 
Understanding the regulation of non-stringent DNA polymerases, such as those of the Y-
family, and how their regulations intercept DNA repair and cell cycle control pathways, 
are key to understanding the role of translesion synthesis in the formation of cancer 
(Lange et al., 2011; Makridakis and Reichardt, 2012). 
While translesion synthesis works toward subtly changing the sequence of genomic 
DNA, not all mutations are detrimental and sometimes new functions are created, such as 
in generating antibody diversity. Somatic hypermutation in activated B cells is an active 
mutagenic process carried out by Y-family DNA polymerases on normal DNA templates 
(Faili et al., 2002; Delbos et al., 2005). The DNA polymerases produce mutations in the 
variable regions of immunoglobulin genes (VH/VL), thus giving rise to antibodies 
recognizing different antigens (McDonald et al., 2003; Delbos et al., 2005; Martomo et 
al., 2005; Faili et al., 2002). 
The behaviors of Y-family DNA polymerases have been studied in the contexts of 
disease and of adaptive immunity. One way to elucidate the functions of Y-family DNA 
polymerases is to find out the DNA lesions they are adept at bypassing. A good example 
of a translesion DNA polymerase that can correctly bypass DNA lesions and thus 
contribute to reducing the incidence of a disease is the human Pol eta.  
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1.2 A brief history of the study of Y-family DNA polymerases 
The human Pol eta gene (POLH or XPV) is defective in some patients with an inherited 
skin disorder called Xeroderma Pigmentosum-Variant (XP-V). Patients with this disease 
are predisposed to sunlight induced skin cancer and their skins retain high levels of 
damage due to DNA lesions, such as cis-syn thymine-thymine dimers arising from UV 
irradiation. Cells of these patients have normal nucleotide excision repair to remove these 
DNA lesions, but lack specialized DNA polymerases to bypass the lesions in DNA 
replication.  
The XPV protein first isolated in HeLa cells is the human Pol eta (Masutani et al., 1999), 
its amino acid sequence shares 20% identity with the Saccharomyces cerevisiae RAD30 
protein that encodes the yeast Pol eta (Johnson et al., 1999). Cell extracts of XP-V 
patients cannot bypass thymine dimers, however, when purified recombinant XPV 
proteins were added there was bypass activity. It was established from this experiment 
that the human Pol eta is able to bypass thymine-thymine dimers in cells and that a defect 
in the POLH gene causes skin disease.  
According to their phylogenetic relationships to yeast RAD30, POLH along with three 
other human DNA polymerase genes (POLK, POLI and REV1) belong to the Y-family 
(Burgers et al., 2001; Ohmori et al., 2001). Over 200 orthologs of Y-family DNA 
polymerase genes have been identified in all three kingdoms of life (Yeiser et al., 2002). 
We would not have learned about those in higher eukaryotes without first identifying 
their homologous genes in yeast and in bacteria—for example, yeast RAD30 was 
discovered by its homology to DinB and UmuC genes in Escherichia coli that encode 
DNA Polymerases IV and V, respectively (McDonald et al., 1997). The study of 
translesion synthesis began in the 1970s (Radman et al., 1974), and using E. coli, a two-
polymerase model was developed to describe translesion synthesis as a process that 
occurs in two steps—insertion and extension, each effected by a different error-prone 
DNA polymerase (Radman et al., 1974). The two-polymerase model is also widely 
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adopted as the mechanism of translesion synthesis in higher eukaryotes (Friedberg et al., 
2005; Shachar et al., 2009). 
The two-polymerase model gained support partly because of the regulation of Y-family 
DNA polymerases by a ring-structured protein called Proliferating Cell Nuclear Antigen 
(PCNA) which functions as a sliding clamp at DNA replication fork (Tsurimoto, 1999; 
Maga and Hübscher, 2003; Naryzhny, 2008). Human PCNA is a homotrimer for which 
each of its subunits can bind to a Y-family DNA polymerase (Kannouche et al., 2004; 
Bienko et al., 2005; Haracska et al., 2005; Guo et al., 2006; Jansen et al., 2007). 
Recruitment of more than one Y-family DNA polymerases by PCNA favored the two-
polymerase model.  
The model also gained support with the evidence that Y-family DNA polymerases co-
localize to replication foci in the nuclei when cells are induced by DNA damage. This 
suggests that the bypass of DNA lesions can be coordinated among the DNA 
polymerases (Kannouche et al., 2003). Furthermore, mutations are observed not only 
opposite to but also adjacent to DNA lesions in cellular studies done using a translesion 
synthesis assay (Avkin and Livneh, 2002; Shachar et al., 2009; Taggart et al., 2013) and 
these mutations are believed to be made by different error-prone DNA polymerases. In 
my work, I will call into question the two-polymerase model and argue that mutations 
adjacent to DNA lesions do not result immediately from translesion synthesis.  
 
1.3 Common features of Y-family DNA polymerases 
The overall structure of a Y-family DNA polymerase resembles a ‘right-hand’ with palm, 
finger and thumb domains that form the protein’s active site (Friedberg et al., 2001). In 
addition, a Y-family DNA polymerase has a domain called the ‘Little Finger’ (Ling et al., 
2001); its amino acid sequence is divergent among Y-family members (Boudsocq et al., 
2004). Tethered to the thumb domain, the ‘Little Finger’ domain binds DNA. It was 
thought that movement of the ‘Little Finger’ domain modulates substrate specificity of Y-
family DNA polymerases, so that each of them is unique in the type of DNA lesions it 
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can bypass (Boudsocq et al., 2004). However, my results show that there are functional 
overlaps among Y-family DNA polymerases in the cell to bypass DNA lesions.  
Y-family DNA polymerases are tolerant of unusual local structures in DNA caused by a 
damaged nucleotide. A major reason is because their active sites have a larger space than 
replicative DNA polymerases, so they can accommodate a base pair mismatch, 
Hoogsteen base pairing or a base flip-out in DNA template caused by a DNA lesion 
(Friedberg et al., 2001). This is not to say that Y-family DNA polymerases do not select 
for incoming nucleotides, but rather, they tend to make flexible choices. Another reason 
that Y-family DNA polymerases can replicate through DNA lesions is that they lack a 3’-
5’ exonuclease or proofreading activity (Friedberg et al., 2001). While this ensures the 
complete bypass of a DNA lesion in that the enzyme does not track backwards to remove 
a nucleotide it has just inserted, the lack of proofreading activity makes the DNA 
polymerases error-prone. The error frequency of a Y-family DNA polymerase on normal 
DNA template is one mistake in every 102 to 104 nucleotides replicated (Ollivierre et al., 
2011; Tissier et al., 2000) compared to one mistake in every 106 to 108 nucleotides 
synthesized by a replicative DNA polymerase that has intrinsic proofreading activity 
(Kunkel, 2004). Unlike replicative DNA polymerases that can incorporate thousands of 
nucleotides in a stretch, Y-family DNA polymerases disengage from the template after 
adding several nucleotides (Ohashi et al., 2000; Friedberg et al., 2001; Boudsocq et al., 
2004). Y-family DNA polymerases are also slower than replicative DNA polymerases in 
catalyzing polymerization reactions (Beard et al., 2002).  
 
1.4 Distinct functions of translesion DNA polymerases  
Each Y-family DNA polymerase was thought to have unique structural properties that 
enable it to bypass different DNA lesions, but Rev1 is an exception because it was first 
discovered as a protein that has nucleotidyl transferase activity in S. cerevisiae and it 
preferentially inserts dCMP opposite abasic site (Nelson et al., 1996). There are at least 
two ways Rev1 can function in translesion synthesis depending on whether its catalytic 
domain is involved.  
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First, it was recently shown that Rev1 can bypass a DNA lesion directly, the Rev1 dCMP 
transferase domain is required to bypass 1,N6-ethenoadenine (Zhou et al., 2010). Second, 
Rev1 can mediate translesion synthesis indirectly by acting as a scaffold, which does not 
require the protein’s catalytic domain to recruit other DNA polymerases, such as Pol 
kappa, Pol eta, Pol iota and Pol zeta (Guo et al., 2003; Ohashi et al., 2004; Tissier et al., 
2004). 
Pol zeta is a B-family DNA polymerase that plays an important role in error-prone 
translesion synthesis (Gan et al., 2008). The Rev3L protein and the Rev7 protein are the 
catalytic subunit and the accessory subunit of Pol zeta, respectively. The REV3L gene is 
essential for mouse embryonic development (Wittschieben et al., 2006). Cells with 
targeted disruption of REV3L have reduced numbers of point mutations and are very 
sensitive to UV light and some DNA damaging agents (Gan et al., 2008; Wittschieben et 
al., 2006). Therefore, Rev3L is essential for bypassing various types of DNA lesions and 
in error-prone translesion synthesis (Jansen et al., 2009). It has been reported that Rev3 
adopts the function of an extender DNA polymerase, acting sequentially after an insertor 
DNA polymerase to extend from a lesion site (Acharya et al., 2006; Lee et al., 2014). 
Rev1 and Rev3L cooperate in translesion synthesis through an interaction mediated by 
Rev7 (Murakumo et al., 2001; Kikuchi et al., 2012). Rev1 and Rev3 also contribute to the 
process of homologous recombination to repair double strand breaks induced in cells by 
ionizing radiation (Sharma et al., 2011; Wittschieben et al., 2010) and post-replication 
gaps resulting from DNA lesions (Jansen et al., 2009). Regulations of Rev1 and Rev3 are 
governed by PCNA and the consequences of Rev1 and Rev3’s interactions are dependent 
on the states of post-translational modifications of PCNA (Hoege et al., 2002; Stelter and 
Ulrich, 2003; Andersen et al., 2008). Mono-ubiquitinlation of PCNA controls the timing 
of translesion synthesis and regulates the access of the Rev3L protein and Y-family DNA 
polymerases to DNA templates (Vidal et al., 2004; Kannouche et al., 2004; Garg et al., 
2005; Bi et al., 2006; Guo et al., 2006; Chun and Jin, 2010).  
Pol iota is considered the most error prone among the four human Y-family DNA 
polymerases (Tissier et al., 2000; Zhang et al., 2000a; Makarova and Kulbachinskiy, 
2012) because it has not yet been shown what kind of DNA lesions Pol iota can bypass 
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correctly. The pol iota gene, arising from an ancestral gene duplication of Pol eta, is not 
essential for survival. Mice with homozygous knockout of the Pol iota gene (POLI) have 
normal phenotypes (McDonald et al., 2003). 
On the other hand, mice with a knockout of the Pol eta gene (POLH) are susceptible to 
developing skin tumors after UV irradiation (Lin et al., 2006). Thus, Pol eta protects 
mammalian cells from DNA damage caused by UV light. 
Pol kappa can replicate past several bulky DNA adducts in vitro, including 
benzo(a)pyrene (Zhang et al., 2000b; Ogi et al., 2002; Ogi and Lehmann, 2006). Mouse 
and chicken cells with complete disruption of the POLK gene grow normally but show 
slightly increased UV sensitivity (Ogi et al., 2002; Okada et al., 2002). Pol kappa on its 
own cannot bypass major UV lesions such as cis-syn T-T dimers in vitro, but it is able to 
extend from a nucleotide inserted to the 3’T of the dimer by another DNA polymerase 
(Carpio et al., 2011; Zhang et al., 2000b). Pol kappa has been shown to act as an extender 
DNA polymerase in translesion synthesis as well as having a role in nucleotide excision 
repair (NER) (Ogi and Lehmann, 2006). 
 
1.5 Project 
The initial aim of my project is to investigate the cellular function of Pol iota on 
bypassing the DNA lesion 8-oxo-guanine. X-ray crystal structures of Pol iota solved by 
former members in the Ling Lab have shown that the DNA polymerase can bypass 8-
oxo-G accurately in vitro (Kirouac and Ling, 2011a). Therefore, by extension, I 
hypothesized that Pol iota can accurately bypass 8-oxo-G in vivo. If this function of Pol 
iota could be confirmed in the cell and that no other Y-family DNA polymerases shared 
the same function, Pol iota would have the indispensable role of protecting cells from 
oxidative stress that produces 8-oxo-G.   
My project expanded to include the study of another DNA lesion, the cisplatin 
instrastrand crosslinked 1,2-d(GpG) or Pt-GG for short. I obtained isogenic mouse 
embryonic fibroblast (MEF) cell lines that allowed me to study translesion synthesis of 
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each of the 8-oxo-G and the Pt-GG lesion by all four of the human Y-family DNA 
polymerases (Pol iota, Pol kappa, Pol eta, Rev1) and Rev3L. 8-oxo-G and Pt-GG would 
make for valuable comparisons because I assumed, as were implicated in literatures, that 
8-oxo-G, a relatively small DNA lesion does not block DNA replication, and that Pt-GG, 
a purine dimer does. In this project, I found that Pt-GG and 8-oxo-G had similar blocking 
effects to DNA replication in mammalian cells.  
From the perspective of generating mutations, interactions between DNA lesions and 
translesion DNA polymerases contribute to shaping the mutational landscape of the cell. 
My work has added knowledge to the mutagenicity of the two DNA lesions 8-oxo-G and 
Pt-GG and to the biological functions of translesion DNA polymerases on bypassing 
these two lesions. 
 
1.6 8-oxo-guanine 
8-oxo-guanine (8-oxo-G) is a very common DNA lesion formed by the chemical reaction 
between a guanine base and reactive oxygen species (Figure 2). 
 
Figure 2  How 8-oxo-guanine is formed. 
Reactive oxygen species such as superoxide radical (O2·
-), hydrogen peroxide (H2O2) and 
hydroxyl radical (·OH) are generated in the body as byproducts of oxygen metabolism 
and are found in the environment. Guanine is the base most prone to DNA oxidation 
(Weimann et al., 2002). The steady state concentration of 8-oxo-G in cells remains in 
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debate because there is no reliable method to accurately measure its concentration 
(Marnett, 2000). The level of 8-oxo-G in human tissues has been reported by several labs 
and the numbers differ widely, ranging from one adduct in 103 nucleotides to one adduct 
in 107 nucleotides (Cadet et al., 1997). While the abundance of 8-oxo-G in genomic DNA 
remains controversial (Marnett, 2000), it is generally considered pretty high (Bohr et al., 
2002; van Loon et al., 2010). Free 8-oxo-G in the cellular nucleotide pool can be 
incorporated into DNA (Satou et al., 2009) and deoxyguanosine in DNA can be directly 
converted to 8-oxo-G. The DNA lesion is removed by DNA glycosylase OGG1 in base 
excision repair pathway (Boiteux and Radicella, 2000; Hazra et al., 2001), and that which 
is not removed causes a high frequency of C->A transversion mutation when replicated 
(Cheng et al., 1992). My study shows that the mutation frequency of 8-oxo-G in 
mammalian cells is very high, in fact higher than all previously reported, and the cell 
lines used should have normal OGG1 genes. This finding underlines the importance of 
DNA repairs, perhaps in addition to the action of DNA glycosylase OGG1, to remove 8-
oxo-G before its replication.  
 
1.7 Repair of 8-oxo-G lesions by base excision repair  
Base excision repair is the predominant pathway for removing 8-oxo-G and other DNA 
damages caused by free radicals and reactive species generated by metabolism (Clancy, 
2008). In mammalian cells, 8-oxoguanine-DNA glycosylase (OGG1) and endonuclease 
III homolog 1 (NTH1) are two enzymes that recognize and cleave oxidized guanine bases 
from DNA (Hailer et al., 2005). First, DNA glycosylase releases a damaged base and thus 
creates an abasic site by cleaving a covalent bond called the N-glycosidic bond between 
the DNA base and ribose sugar. Then, apurinic/apyrimidinic (AP) endonucleases cleaves 
the phosphodiester bond in DNA at the abasic site and makes a single stranded break. 
The break is repaired by either DNA synthesis with strand displacement (long-patch 
pathway) or by another pathway (called short patch) that removes the 5’ deoxyribose 
phosphate group at the abasic site by enzymes with 5’ deoxyribose phosphatase lyase 
activity followed by DNA synthesis. The final step of both pathways is sealing of the 
single stranded gap by DNA ligase. OGG1 knockout mice accumulate more 8-oxo-G 
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lesions in hepatocytes but not in splenocytes, spermatocytes and kidney cells (Minowa et 
al., 2000; Osterod et al., 2001). OGG1-deficient fibroblast culture does not accumulate 
more 8-oxo-G lesions than the control wild type fibroblast culture. NTH1 knockout mice 
are healthy (Ocampo et al., 2002). Both OGG1-deficient mice and NTH1-deficient mice 
do not have association with increased incidence of cancer, suggesting that there are other 
base excision repair enzymes in mammalian cells that recognize and remove 8-oxo-G 
lesions (Dou et al., 2003; Hailer et al., 2005). MUYTH is a DNA glycosylase in human 
that excises an adenine base mispaired with 8-oxo-G. Mutations in the MUTYH gene are 
associated with heritable predisposition to colorectal cancer.  
 
1.8 Cisplatin intrastrand crosslinked 1,2-d(GpG) 
Cisplatin is an anti-tumor agent used for treating a variety of cancers. Pt-GG is a major 
species (65%) of the various types of interstrand and intrastrand cisplatin-DNA adducts 
formed in cancer patients (Fichtinger-Schepman et al., 1987; Jung and Lippard, 2007; 
Cepeda et al., 2007). It is believed that cisplatin kills rapidly dividing tumor cells partly 
because Pt-GG blocks DNA replication (Vaisman et al., 2000; Chijiwa et al., 2010). 
 
 
Figure 3  How Pt-GG is formed. 
Cisplatin crosslinks the N7 atoms of adjacent guanosine nucleotides within the same 
DNA strand to form Pt-GG (image was provided by colleague Chuanbing Bian).  
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Following this rationale, the tumor cell develops resistance to cisplatin when it has 
acquired the ability to bypass cisplatin-DNA lesions and particularly, when the bypass of 
the lesion inserts the correct nucleotides. Researchers studying translesion synthesis of 
Pt-GG saw DNA polymerases with the ability to bypass the lesion as potential drug 
targets in chemotherapy. They postulated that drugs inactivating these DNA polymerases 
would reduce cisplatin resistance in cancer treatment (Zhao et al., 2012). 
In my study, I found that Pt-GG was bypassed correctly 99% of the time in the 
mammalian cell due to DNA polymerase(s) other than those of the Y-family and other 
than Rev3L. The translesion DNA polymerases bypassed Pt-GG in an error-prone 
manner, and these enzymes were responsible for cisplatin resistance to the extent that 
they could bypass the DNA lesion. This result implies that the drug mechanism of 
cisplatin was likely not due to the direct effect of Pt-GG on blocking DNA replication, 
because the lesion was bypassed relatively efficiently and by several DNA polymerases 
in the cell. On the other hand, cisplatin also generates interstrand DNA adducts, and it is 
conceivable that these DNA lesions would be highly blocking to DNA replication and 
may therefore be responsible for the drug’s cytotoxicity.  
 
1.9 Repair of Pt-GG lesions by nucleotide excision repair 
Nucleotide excision repair (NER) is the predominant pathway for removing bulky and 
dinucleotide DNA lesions, such as cyclobutane-pyrimidine dimers and 6-4 photoproducts 
induced by UV radiation. Nucleotide excision repair is also thought to be the major 
pathway for removing Pt-GG lesions (Nouspikel, 2009; Wang et al., 2011). In 
mammalian cells, there are at least 18 protein complexes involved in nucleotide excision 
repair (Clancy, 2008), and defects in some of the proteins are associated with the diseases 
Xeroderma Pigmentosum and Cockayne Syndrome (Nouspikel, 2009). In nucleotide 
excision repair, distortion in local DNA structure caused by Pt-GG is recognized by 
proteins XPA, RPA and the XPC-hHR23B complex, then the two strands of DNA around 
the lesion are pried apart by the DNA helicase TFIIH in an ATP-dependent manner. The 
strand containing the lesion is cleaved at the 3’ end by XPG nuclease and at the 5’ end by 
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the ERCC1-XPF nuclease, thereby releasing a short DNA fragment that is 24-32 
nucleotides long (Wood, 1997). Synthesis across the short gap is carried out by the 
holoenzymes of DNA polymerase δ or ε, mediated by PCNA and finally, the single 
stranded gap is sealed by DNA ligase (Wood, 1997).  It was also reported that mismatch 
repair could be involved in repairing Pt-GG lesions because the human mismatch repair 
protein hMSH2 binds to Pt-GG (Duckett et al., 1996; Mello et al., 1996). The 
mechanisms for removing Pt-GG lesions are different from that for removing 8-oxo-G 
lesions. 
 
1.10 Translesion synthesis assays 
To study mutations arising from DNA lesions in mammalian cells, I used a quantitative 
translesion synthesis (TLS) assay (Ziv et al., 2012). To deduce the functions of 
translesion DNA polymerases on bypassing the lesions in vivo, I obtained pairs of 
isogenic mouse embryonic fibroblast cell lines that were generated from knockout mice, 
where the mutant cell lines have specific knockouts of translesion DNA polymerases. I 
could infer the biological function of a DNA polymerase by comparing a mutant cell line 
to its isogenic wild type cell line. In the TLS assay, double stranded plasmids containing 
a small gap with and without a site-specific DNA lesion are co-transfected in equal 
amounts into mammalian cells, inside which the plasmids do not replicate but their gaps 
are filled. Then the plasmid DNAs are retrieved from the cell by the alkaline lysis 
method, which ensures that only the fully double stranded plasmids are retained and any 
unfilled or unrepaired gap plasmids are removed. Then I focused on two questions: First, 
what are the nucleotides that have been incorporated against the DNA lesions and second, 
what is the efficiency at which the lesion gap plasmid is repaired relative to the control 
gap plasmid, in other words, what is the efficiency at which the DNA lesion is bypassed 
relative to a regular nucleotide. I used two different approaches to address these 
questions: the traditional TLS assay and the high-throughput TLS assay. The traditional 
TLS assay uses E. coli to amplify the plasmids and Sanger Sequencing to determine the 
plasmid sequences (Ziv et al., 2012). The high-throughput TLS assay, which is one of the 
innovations in my project, uses PCR to amplify the gap regions of the plasmids and Next 
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Generation Sequencing to determine their sequences. The two approaches generated very 
different results that would make for an interesting comparison of the immediate effect 
versus the long term effect of a DNA lesion in the cell.  
One of the advantages of the translesion synthesis assay is that the lesion gap plasmid is 
introduced into the cell along with the control gap plasmid that does not have a DNA 
lesion. Thus, the blocking effect of a DNA lesion can be measured by comparing the gap 
filling efficiency of the lesion plasmid relative to that of the control plasmid.  
There are two major assumptions of the translesion synthesis assay. First, a DNA lesion 
in the gap plasmid is not removed in the cell prior to gap-filling. Second, a mismatched 
base pair resulting from translesion synthesis is preserved and unaltered when the 
plasmid is incubated in the mammalian cell. It has been shown that base excision repair is 
not active in the seven-hour period following transfection of the gap plasmids into the 
mammalian cell (Ziv et al., 2012).  
An alternative substrate to use in the TLS assay is a single stranded gap plasmid that 
replicates in the mammalian cell (Karata et al., 2009; Pandya and Moriya, 1996; Watt et 
al., 2007). Some investigators have argued that this is a better model than the double 
stranded gap plasmid model to study translesion synthesis in DNA replication because 
the latter simulates gap-filling in DNA repair processes that occur in a different cell cycle 
stage. It has been shown, however, that translesion DNA polymerases are active in the 
late S and G2 phases of the cell cycle when the double stranded gap plasmid is being 
repaired (Daigaku et al., 2010; Karras and Jentsch, 2010; Diamant et al., 2011). 
Therefore, the double stranded gap plasmid is an appropriate substrate for studying 
mutations produced by translesion DNA polymerases.  
The traditional TLS assay has several drawbacks. First, to study the spectrum of 
mutations caused by a DNA lesion, the traditional TLS assay uses E. coli to amplify and 
separate the control plasmids and lesion plasmids prior to Sanger sequencing. This makes 
the results questionable because the DNA sequences can undergo additional changes in 
bacteria as bacterial cells divide and multiply. Second, to study the bypass efficiency of a 
DNA lesion, the traditional TLS assay takes the ratio of the number of bacterial colonies 
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arising on a kanamycin plate, which selects for the lesion plasmids, to that arising on a 
chloramphenicol plate, which selects for the control plasmids. Since bacteria have 
different growth preferences in culturing media with different antibiotics, this method of 
measuring the translesion synthesis efficiency is flawed. Third, the traditional TLS assay 
is inefficient, and thus limits the amount of sequence information that can be obtained 
from each transfection experiment; any conclusions drawn from a small number of 
samples are misleading.   
In adapting the traditional TLS assay into a high-throughput TLS assay, I replaced the 
steps in the traditional TLS assay that used E. coli with PCR, so instead of amplifying the 
whole plasmid in bacteria, a small region on the plasmid was amplified in a test tube. I 
designed a multiplexed study of the two DNA lesions 8-oxo-G and Pt-GG, which were 
acted upon by each of the five translesion DNA polymerases (Pol iota, Pol kappa, Pol eta, 
Rev1 and Rev3). I used barcoded primers in PCR reactions to keep track of DNA 
samples of different transfection experiments and pooled all the PCR products together to 
do Next Generation Sequencing (NGS). For positive control, I used fully double stranded 
plasmids with known sequence in PCR reactions to monitor experimental errors. For 
negative control, I incubated gap plasmid mixture with mammalian cells in the absence of 
transfection reagent to show that only plasmids that had been repaired in cells and were 
double stranded would be preserved (not destroyed by alkaline lysis) and sequenced. A 
control that is missing is to use the lesion gap plasmid as template in PCR reaction to 
check the effect of recombinant DNA polymerase used in PCR. The high-throughput 
TLS assay generated thousands and tens of thousands of sequences for each transfection 
experiment, so the NGS technology greatly increased the sample size and the statistical 
power of my study. Before implementing the high-throughput TLS assay, however, I 
obtained some results using the traditional TLS assay. I will reconcile the difference in 
findings of the two methods in the Discussion section.  
 
1.11 Objectives and hypotheses 
This thesis can be read with a focus on any of the following three dimensions:  
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1) The mutagenic properties of the two DNA lesions 8-oxo-G and Pt-GG in terms of 
their mutation frequency (Section 3.1 & 3.6), mutation spectrum (Section 3.2 & 3.7) and 
bypass efficiency (Section 3.12). Comparisons were made between the control plasmids 
and the lesion plasmids to elucidate the effect of a DNA lesion. Properties of 8-oxo-G 
lesion and Pt-GG lesion were compared in the Discussion (Section 4.3).  
2) The roles of the translesion DNA polymerases Pol iota, Pol eta, Pol kappa, Rev1 
and Rev3L on the bypass of either 8-oxo-G (Section 3.4 & 3.5) or Pt-GG (Section 3.8-
3.11). Comparisons were made between a cell line that is wild type for a particular 
translesion DNA polymerase gene and its isogenic mutant cell line that is deficient for 
that gene to deduce the in vivo functions of the translesion DNA polymerase (Appendix 
E). 
3) A comparative and critical analyses of the results obtained from the traditional TLS 
assay and those obtained from the high-throughput TLS assay. In the discussion section, 
results of the traditional TLS assay and those of the high-throughput TLS assay are 
compared (Section 4.1) and reconciled (Section 4.7 to 4.9).  
In the early phase of this project, I formulated hypotheses based on the reasoning that if a 
DNA polymerase has the ability to bypass a particular DNA lesion correctly in vitro, it 
would also have a similar function in vivo. My first hypothesis is that Pol iota can 
accurately bypass 8-oxo-G lesions in mammalian cells (Section 3.4). My second 
hypothesis is that Pol eta can accurately bypass Pt-GG lesions in mammalian cells 
(Section 3.8). Because the POLI gene is phylogenetically related to the POLH gene, Pol 
iota and Pol eta might have similar functions; I further hypothesized that Pol iota, in 
addition to Pol eta can correctly bypass Pt-GG in cells (Section 3.9). This last hypothesis 
sought to complement the work of Chuanbing Bian, my colleague who was working on 
determining the kinetics and solving the X-ray crystal structures of Pol iota on bypassing 
the Pt-GG lesion. All three of the hypotheses were first investigated by the traditional 
TLS assay and later by the high-throughput TLS assay.  
The high-throughput TLS assay extended the scope of my project beyond the initial 
hypotheses. I used the assay to determine the mutagenic properties of 8-oxo-G and Pt-GG 
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and to explore which of the translesion DNA polymerases (Pol iota, Pol eta, Pol kappa, 
Rev1 and Rev3) bypassed the DNA lesions in mammalian cells. Data of the high-
throughput TLS assay could not be analyzed in the same way that data of the traditional 
TLS assay were analyzed. At first, I thought results of the high-throughput TLS assay 
would validate those of the traditional TLS assay, but it turned out not to be the case.   
 
1.12 Significance 
A change in methodology from the traditional TLS assay to the high-throughput TLS 
assay led to new understandings about the properties of the two DNA lesions 8-oxo-G 
and Pt-GG and about translesion synthesis in the mammalian cell. My project generated 
new hypotheses about the in vivo functions of translesion DNA polymerases, overturned 
previous assumptions on the blocking effects of the two DNA lesions, and called into 
question the two-polymerase model. 
Results of the traditional TLS assay are totally different from those of the high-
throughput TLS assay even though they are all produced from the same initial condition, 
which is a single DNA lesion in the gap plasmid. The high-throughput TLS assay 
captured a still photograph and the traditional TLS assay captured a time-lapsed 
photograph of mutations arising from a DNA lesion. The results of the two methods 
provided insights into the immediate versus the long-term effect of a DNA lesion, where 
the latter had been influenced by the selective pressure of the cell.  
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Chapter 2  
2 Materials and methods 
 
2.1 Plasmids  
Two plasmids, pSKSL-CmR (3618 bp) and pSKSL-KanR (3365 bp), were obtained from 
Omer Ziv from Dr. Zvi Livneh’s laboratory (Weizmann Institute of Science). The 
sequences of the two plasmids are almost identical except for their antibiotic markers. 
The pSKSL-CmR plasmid with a chloroamphenicol (Cm) selectable marker was used to 
make the control gap plasmid that does not have a DNA lesion. The pSKSL-KanR 
plasmid with a kanamycin (Kan) selectable marker was used to make the lesion gap 
plasmid that has a site-specific DNA lesion, either 8-oxo-G or Pt-GG.  
The sequence of the pSKSL-KanR plasmid was modified twice by QuikChange® PCR 
(Stratagene, 2005). After the first modification, the plasmid was used to construct the 
lesion gap plasmid containing 8-oxo-G. Based on the first modification, additional 
changes were made in the sequence of the pSKSL-KanR plasmid by a second 
QuikChange PCR reaction. The resulting plasmid was used to construct the lesion gap 
plasmid containing Pt-GG.   
 
2.2 QuikChange® PCR  
Primers were designed for each QuikChange® PCR reaction to make three nucleotide 
substitutions in the pSKSL-KanR plasmid. Sequences of the primers for the two 
QuikChange® PCR reactions are listed in Table 1. QuikChange® PCR reactions were 
carried out as previously described (Stratagene, 2005). Nucleotide substitutions in the 
plasmids were confirmed by sequencing. 
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Table 1  Primers used in QuikChange PCR reactions to make three nucleotide 
substitutions in the pSKSL-KanR plasmid 
The first QuikChange® PCR reaction  
Template:  pSKSL-KanR plasmid DNA as it was received 
Forward 
primer:  
1LG136-
oligo 1  
GCCCGTCGTGTAGATAACTAACGTACGGGAGGGCTTACCATC 
(42 bases, GC content 55%, % mismatch to the template: 3/42 bases,  
Tm calculated by the Stratagene formula: 81°C) 
Reverse 
primer: 
1LG136-
oligo 2 
GATGGTAAGCCCTCCCGTACGTTAGTTATCTACACGACGGGC 
(42 bases, GC content 55%, % mismatch to the template: 3/42 bases,  
Tm calculated by the Stratagene formula: 81°C) 
Note: ‘CAG’ in the template was modified to ‘ACG’ as bolded and 
underlined in the primer sequences. 
 
The second QuikChange® PCR reaction 
Template: pSKSL-KanR plasmid that has been modified by the first QuikChange® 
PCR 
Forward 
primer: 
4LG94-L 
ACTGCCCGTCGTGTAGATAAGTGACGTACGGGAGGGCTTACC 
(42 bases, GC content 57%, % mismatch to the template: 3/42 bases,  
Tm calculated by the Stratagene formula: 82°C)  
Reverse 
primer: 
4LG94-R 
GGTAAGCCCTCCCGTACGTCACTTATCTACACGACGGGCAGT  
(42 bases, GC content 57%, % mismatch to the template: 3/42 bases, 
Tm calculated by the Stratagene formula: 82°C).  
Note: ‘CTA’ in the template was modified to ‘GTG’ as bolded and underlined 
in the primer sequences. Right after ‘GTG’ is ‘ACG’ from the first 
modification.  
 
2.3 Oligonucleotides with site-specific DNA lesions 
54mer oligos containing 8-oxo-G were synthesized at the W. M. Keck Oligonucleotide 
Synthesis Facility (Yale). The sequence of the 54mer oligo is 
ACCGCAACGAAGTGATTCCGGCATGCXTCCTACCTGGCTACTTGAACCAGACCG, 
where X denotes 8-oxo-G and the sequence of the single stranded gap region is 
underlined. The oligos were purified in our lab by anion exchange chromatography using 
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a SOURCE 15Q column (GE Healthcare) on ÄKTAFPLC system (GE Healthcare). 
54mer oligos containing Pt-GG were made by ligating three shorter oligos (5’-end 21mer, 
3’-end 21mer and 12mer) together in the presence of a 34mer scaffold DNA (Table 2). 
The sequence of the 54mer oligo is 
ACCGCAACGAAGTGATTCCGGCTTCCTCTGGCCCTGGCTACTTGAACCAGACCG, 
where GG denotes Pt-GG and the sequence of the single stranded gap region is 
underlined.  
12mer oligos with Pt-GG were made by Chuanbing Bian in our lab following an 
established protocol (Zhao et al., 2012). 1.8nmol of the 5’-end 21mer oligos, 1.8nmol of 
the 3’-end 21mer oligos and 1.5nmol of the 12mer oligos were 5’-phosphorylated using 
T4 polynucleotide kinase (NEB). The three phosphorylated oligos were combined, 
annealed to 1.8nmol of the 34mer scaffold oligos, and then ligated using T4 DNA ligase 
(NEB) in the presence of 1mM ATP. The 54mer ligated products were separated from 
any unligated oligos and scaffold DNAs on an 8M urea 12% polyacrylamide gel. The gel 
was ran under constant power of 30-50 Watts for one hour (Figure 5). The 54mer 
products were extracted from the gel, purified and re-suspended in a final concentration 
of 15pmol/µl.   
Table 2  Sequences of the shorter oligos for making the 54mer oligo containing Pt-
GG 
5’-end 21mer ACCGCAACGAAGTGATTCCGG 
12mer with Pt-GG (red) CTTCCTCTGGCC 
3’-end 21mer CTGGCTACTTGAACCAGACCG  
34mer scaffold AAGTAGCCGGGGCCAGAGGAAGCCGGAATCACTT 
 
2.4 Construction of double stranded gap plasmids 
150pmol of the 54mer oligos, 240pmol of the upstream 15mer primer and 240pmol of the 
downstream 15mer primer were 5’-phosphorylated. They were annealed to make gap 
duplexes. 150pmol of the gap duplexes were ligated into 100pmol of linearized DNA 
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vectors in a large-scale ligation reaction using 60,000 units of T4 DNA ligase in a total 
final volume of 12ml. The DNA vectors were prepared by digesting 600µg of the 
pSKSL-CmR or p-SKSL-KanR plasmid DNAs with 300 units each of the BsaI and BstXI 
restriction enzymes, and isolating the larger DNA fragment (around 3kb) by gel 
purification. After ligation, DNA was concentrated by ethanol precipitation. The singly 
ligated gap plasmids were separated from any unligated DNA vectors and multiply 
ligated DNA products by gel purification and electroeluted. The isolated gap plasmids 
were concentrated by ethanol precipitation and desalted using an Amicon Ultra-0.5mL 
Microcon® column (Ultracel 3K Membrane, Millipore).  The concentration of the 
purified gap plasmids was measured by NanoDrop. 
Table 3  Sequences of the two 15mer oligos annealing to the 54mer oligo for making 
the gap duplex 
Upstream 15mer primer GGAATCACTTCGTTG 
Downstream 15mer primer CTGGTTCAAGTAGCC 
 
2.5 Cell lines and cell culture 
Isogenic pairs of immortalized mouse embryonic fibroblast (MEF) cell lines with 
knockout(s) of one or a few translesion DNA polymerase genes were obtained (Table 4). 
A pair of Burkitt’s lymphoma (BL2) cell lines, one wild type and one POLI-deficient, 
was also obtained (Table 4). 
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Table 4  Mammalian cell lines with various knockouts of translesion DNA 
polymerase genes 
Cell line and genotype Nick-
name 
Sender / Laboratory Reference 
MEF POLI (+/+) 724-
1SV 
Dr. Woodgate (National 
Institute of Child 
Health and Human 
Development, USA)  
(McDonald et al., 
2003) 
MEF POLI (-/-) 725-
3SC 
Dr. Woodgate (McDonald et al., 
2003) 
BL2 POLI(+/+)  Dr. Woodgate (Faili et al., 2002) 
BL2 POLI(-/-) 267 Dr. Woodgate (Faili et al., 2002) 
MEF POLH(+/+) B3 K. Hashimoto, Moriya 
Lab (Stony Brook 
University, New York)  
(Ohkumo et al., 
2006) 
MEF POLH(-/-)  K. Hashimoto, Moriya 
Lab 
(Ohkumo et al., 
2006) 
MEF POLK(+/+)  K. Hashimoto, Moriya 
Lab 
(Ogi et al., 2002) 
MEF POLK(-/-)  K. Hashimoto, Moriya 
Lab 
(Ogi et al., 2002) 
MEF  
POLH(-/-) POLI(-/-) 
 K. Hashimoto, Moriya 
Lab 
(Ohkumo et al., 
2006) 
MEF  
POLK(-/-) POLI(-/-) 
 K. Hashimoto, Moriya 
Lab 
(Hashimoto et al., 
2012) 
MEF  
POLH(-/-) POLI(-/-) 
POLK(-/-)  
2091 K. Hashimoto, Moriya 
Lab 
(Hashimoto et al., 
2012) 
MEF  
POLH(-/-) POLI(-/-) 
POLK(-/-) 
2095 K. Hashimoto, Moriya 
Lab 
(Hashimoto et al., 
2012) 
MEF REV1(+/+)  Dr. Niels de Wind 
(Leiden University 
Medical Center, 
Netherlands) 
(Jansen, 2006) 
MEF REV1(-/-)  Dr. Niels de Wind (Jansen, 2006) 
MEF REV3L (+/lox) Cre 3(+)6 L. Sabine, Wood Lab 
(MD Madison Cancer 
(Lange et al., 2012) 
23 
 
Center, Texas)  
MEF REV3L (-/lox) Cre 4(-)5 L. Sabine, Wood Lab  (Lange et al., 2012) 
MEF REV3L (-/lox) Cre 4(-)11 L. Sabine, Wood Lab (Lange et al., 2012) 
MEF  
REV3L(+/+) P53(-/-) 
B2 L. Sabine, Wood Lab  (Wittschieben et al., 
2006) 
MEF  
REV3L(-/-) P53(-/-)  
B4-9 L. Sabine, Wood Lab (Wittschieben et al., 
2006) 
MEF  
REV3L(-/-) P53(-/-) 
B4-18 L. Sabine, Wood Lab (Wittschieben et al., 
2006) 
 
Mouse embryonic fibroblast (MEF) cell lines were cultured in Dulbecco’s Modified 
Eagle’s Medium (DMEM) with 4.5g/L glucose and sodium pyruvate, adding 1x 
GlutaMAX (Invitrogen), 10% new born calf serum (Wisent), and penicillin (100 IU) and 
streptomycin (100ug/ml). Cells were passaged with 0.25% trypsin 2.21mM EDTA 
solution. Burkitt’s lymphoma (BL2) cells grow in suspension. BL2 cell lines were 
cultured in RPMI 1640 medium with L-glutamine and sodium bicarbonate (Wisent), 
adding 10% fetal bovine serum (Wisent), and penicillin (100IU) and streptomycin 
(100ug/ml). The cell lines were maintained at 37°C in 5% CO2 environment chamber.  
 
2.6 Transient Transfection 
Cells were seeded at a density of 2x105 cells per 35mm dish the day before transfection. 
33ng of the control gap plasmids, 33ng of the lesion gap plasmids and 2µg of the carrier 
plasmids (pBlueScript) were transfected into cells using jetPRIME® reagent (Polyplus 
TransfectionTM), as per manufacturer’s recommendations. Cells were incubated for seven 
hours.  
 
2.7 Traditional TLS assay 
Mammalian cells that had been transfected with gap plasmids were harvested and washed 
three times with PBS. The plasmids were extracted by the alkaline lysis method using a 
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plasmid Miniprep kit (Invitrogen). Plasmid DNAs were transformed into E. coli 
(CSH117 strain) by electroporation. Bacterial cells were plated in triplicates on 
chloramphenicol (30µg/ml) and kanamycine (50µg/ml) plates to separate the control 
plasmids and the lesion plasmids, respectively. Translesion synthesis efficiency was 
determined by taking the ratio of the average number of bacterial colonies arising on the 
kanamycin plates to that arising on the chloramphenicol plates. Isolated bacterial colonies 
were inoculated into LB starter cultures and grown overnight. Plasmid DNAs were 
extracted and their sequences were determined by Sanger Sequencing.  
 
2.8 Statistical analyses of traditional TLS assay  
To determine if the POLI gene has an effect on bypassing 8-oxo-G, two-tailed Fisher’s 
Exact Test (Fisher, 1922) was used to determine if the number of sequences with 
mutation across from a DNA lesion of the POLI wild type cell line is significantly 
different from that of an isogenic POLI-deficient cell line. A two by two contingency 
table was set up for computing the exact P-value (Weisstein), whereby the two groups 
compared are POLI wild type cell line and its isogenic POLI(-/-) cell line and the two 
outcomes are “no mutation” and “with mutation” across from the DNA lesion. If the 
computed P-value is less than α of 0.05, the difference in observations between the two 
cell lines is deemed statistically significant. The same method was used to determine if 
the POLH gene and the POLI gene each had an effect on bypassing Pt-GG.   
 
2.9 Quantitative PCR 
Q-PCR reactions were used to measure copy numbers of the control plasmids and lesion 
plasmids extracted from mammalian cells. The ratio of the number of copies of the lesion 
plasmids to that of the control plasmids (Kan/Cm) is the translesion synthesis efficiency. 
A 72 bp fragment of the chloramphenicol resistant gene of the control plasmids and a 71 
bp fragment of the kanamycin resistant gene of the lesion plasmids were amplified using 
the primers listed in Table 5. Melting curve analyses showed that the primers were 
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specific for amplifying their respective targets. Standard curves were plotted using known 
concentrations of each of the control plasmids and lesion plasmids from 5ng/µl to 5x10-
6ng/µl in ten-fold serial dilutions. Concentrations of unknown samples were interpolated 
from the standard curves. 
Table 5  Sequences of Q-PCR primers used to measure copy numbers of the control 
plasmids and the lesion plasmids extracted from mammalian cells 
Primers amplifying from the control plasmids 
Left GGGAAATAGGCCAGGTTTTC (20bp, Tm=59.8°C, GC content 50%)  
Right CGATTTCCGGCAGTTTCTAC (20bp, Tm=59.7°C, GC content 50%)  
Primers amplifying from the lesion plasmids  
Left  AGAAACAACTCTGGCGCATC (20bp, Tm=60.4°C, GC content 50%) 
Right  GATAATGTCGGGCAATCAGG (20bp, Tm=60.3°C, GC content 50%)  
In an earlier experiment, four DNA samples (3LG188.1, 3LG188.2, 3LG102.5 and 
3LG102.6) were measured. A typical Q-PCR reaction consisted of 2µl left primer (1µM 
stock), 2µl right primer (1µM stock), 1µl DNA extracted from mammalian cells or 1µl 
DNA standard, and 5µl 2x EvaGreen qPCR Master Mix. Reactions were set up in 
replicates and ran on Eppendorf RealPlex Mastercycler. The thermocycling condition 
was 95°C 2 min, 35 cycles of 95°C 20 s, 57°C 20 s and 72°C 35 s, then 72°C 10 min.  
In a later experiment, the translesion synthesis efficiencies of 8-oxo-G and Pt-GG were 
determined from each of the nine MEF cell lines with the following genotypes: 
POLI(+/+), POLI(-/-), POLH(+/+), POLH(-/-), POLK(+/+), POLK(-/-), POLH(-/-) and 
POLI(-/-), POLK(-/-) and POLI(-/-), and 2091 POLH(-/-) POLK(-/-) and POLI(-/-). For 
each cell line, three biological replicates were used and each biological replicate was 
measured in triplicates. Q-PCR reactions were set up on a 384-well plate using SYBR 
Select Master Mix (Invitrogen) and ran on the ViiA7TM Real-Time PCR System. The 
thermocycling condition was 50°C 2 min, 95°C 2 min, 95°C 15 s, 40 cycles of 95°C 15 s, 
57°C 15 s and 72°C 1 min. 
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2.10 High-throughput TLS assay 
The gap regions of the plasmids extracted from mammalian cells were amplified by PCR 
using primers that contain barcodes and Illumina adapter sequences. Twenty-four 
barcodes were embedded in left primers and right primers, respectively. The primers 
were ordered from Integrated DNA Technologies in 25nmole scale. 
In the 8-oxo-G study, the control plasmids and lesion plasmids of a transfection 
experiment were amplified in the same PCR reaction. They would be separated 
computationally based on a three nucleotide difference in their sequences. The sequence 
of the plasmid-specific portion of the left primer is GACTGCCCGTCGTGTAGATAA, 
and that of the plasmid-specific portion of the right primer is 
AGCGGTCTGGTTCAAGTAGC. A PCR reaction was set up using 11.8µl water, 4µl 5x 
HF Phusion buffer (Thermo Scientific), 0.4µl 10mM dNTP, 0.8µl left primer (5uM 
stock), 0.8µl right primer (5uM stock), 2µl plasmid DNA extracted from mammalian 
cells, and 0.2µl Phusion Hot Start DNA Polymerase (2U/µl, Thermo Scientific). The 
thermocycling condition was 98°C 30 s, 25 cycles of 98°C 10 s, 66°C 20 s and 72°C 15 s, 
and lastly 72°C 5 min. There are 192 transfection experiments in the 8-oxo-G study, 
including nine biological replicates for each of the twenty cell lines and positive and 
negative controls.  
In the Pt-GG study, the control plasmids and the lesion plasmids of a transfection 
experiment were amplified in two separate PCR reactions using different left primers and 
a common right primer. The sequence of the plasmid-specific portion of the left primer 
used to amplify the control plasmid is CCCGTCGTGTAGATAACTACGA, and that 
used to amplify the lesion plasmid is GCCCGTCGTGTAGATAAGTGA. The sequence 
of the right primer is the same as that used in the 8-oxo-G study. A typical PCR reaction 
consisted of 8.2µl water, 4µl 5x HF Phusion buffer, 0.6µl DMSO, 0.4µl 10mM dNTP, 
0.8µl left primer (5uM stock), 0.8µl right primer (5uM stock), 5µl plasmid DNA 
extracted from mammalian cells and 0.2µl Phusion Hot Start DNA Polymerase (2U/µl). 
Two rounds of DNA amplifications were carried out for a total of 55 PCR cycles. The 
first PCR reaction was ran 98°C 30 s, 25 cycles of 98°C 10 s and 72°C 15 s, and ended at 
72°C 5 min. DNA products were purified and then used as templates in the second PCR 
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reaction. There are 384 barcoded samples in the Pt-GG study. They came from 192 
transfection experiments, including nine biological replicates for each of the twenty cell 
lines and positive and negative controls.  
PCR products of the 8-oxo-G and Pt-GG studies were purified, and their concentrations 
were measured using a Qubit® dsDNA High Sensitivity Assay Kit (Invitrogen). 10ng of 
each of the 576 barcoded DNA samples were combined and further concentrated, then 
the DNA sample was sequenced using 2 by 150 Illumina MiSeq (Robarts Institute).  
 
2.11 Processing Next Generation Sequencing raw data 
Two FASTQ files were generated from the MiSeq run (Appendix 4), one file contains 
reads sequenced in the forward direction (R1) and the other file contains reads sequenced 
in the reverse direction (R2). Each file was processed independently following the same 
procedures. Briefly, reads of the PhiX genome were removed using BOWTIE2, a read 
alignment tool (Langmead and Salzberg, 2012). FASTQ/A Short-reads Pre-processing 
Tools (Hannon Lab, Cold Spring Harbor Laboratory) were used to trim, clip and split 
data. Reads with the same barcodes were grouped and then further split into control 
plasmids and lesion plasmids, and those that don’t match to barcodes were discarded. All 
the sequences were trimmed to 25 bases including the 12-nucleotide gap region. Base 
substitutions of every nucleotide in the gap region were tallied using a ‘NGS Position 
Counter’ program (Taggart et al., 2013). To count the number of reads of different 
permutations of dinucleotides, such as those opposite the Pt-GG lesion, a Perl script 
given to me by Greg Gloor was used to parse the data.  
 
2.12 Statistical analyses of Next Generation Sequencing data 
The same care was taken to analyze reads of the control plasmids and reads of the lesion 
plasmids. The overall mutation frequencies across from 8-oxo-G or Pt-GG were 
calculated based on the sum total of reads obtained for each DNA lesion, regardless of 
the genotype of cell lines. The mutation frequency of the lesion plasmids was compared 
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to that of the control plasmids to elucidate the effect of a DNA lesion. To understand how 
the mutation spectrums differ between the control plasmids and the lesion plasmids, 
principal component analysis (Aitchison, 2003) was applied. The CoDaPack Software 
2.01 (Comas-Cufi and Thió-Henestrosa, 2011) and the compositions package in R (van 
den Boogaart and Tolosana-Delgado, 2008) were used to generate biplots. A biplot shows 
the correlations among variables between the control plasmids and the lesion plasmids, 
and the relative proportions of changes in the variables effected by a DNA lesion.  
To infer the biological function of a translesion DNA polymerase on the bypass of a 
certain DNA lesion, results from two isogenic cell lines were compared. See Appendix E 
for a list of all the cell lines compared, both for the control plasmids and for the lesion 
plasmids in the high-throughput TLS assay. For each cell line and for each of its nine 
biological replicates, the within-sample ratios were calculated and log2 transformed. In 
the 8-oxo-G study, the within-sample variables are log2(A/C), log2(T/C), log2(G/C) and 
log2(deletion/C). In the Pt-GG study, the within-sample variables are log2(CT/CC), 
log2(AT/CC), log2(CG/CC), log2(AG/CC), log2(C/CC), log2(TC/CC), log2(GC/CC), 
log2(AC/CC), log2(A/CC), log2(CA/CC), log2(AA/CC), log2(double deletions/CC). 
Wilcoxon Rank Sum Test was used to compare each of the variables between a pair of 
isogenic cell lines (N=9) and to calculate P-values. P-values were adjusted by the 
Benjamini-Hochberg method (Benjamini and Hochberg, 1995). Where the adjusted P-
values were less than 0.05 (α), the effect sizes (Cohen’s d) and their 95% confidence 
intervals (C.I.) were calculated and the biological functions of the translesion DNA 
polymerases were deduced based on the genotypes of the cell lines being compared. 
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Chapter 3  
3 Results 
 
3.1 Construction of double stranded gap plasmids containing an 8-
oxo-G or Pt-GG lesion 
To study mutations in mammalian cells caused by a DNA lesion, I constructed double 
stranded gap plasmids containing a site-specific 8-oxo-G or Pt-GG lesion. The gap 
plasmids were transfected into mammalian cells as the first step in the translesion 
synthesis assay. To produce double stranded gap plasmids, gapped duplexes were ligated 
into double stranded DNA vectors as shown in Figure 4. Each gap duplex was formed by 
annealing two short primers to a 54 mer oligonucleotide containing a DNA lesion. The 
54mer oligo was produced by bridging together three shorter oligos that had been 5’-
phosphorylated, in the presence of a 34mer scaffold DNA, and the final product was 
purified by denaturing PAGE (Figure 5). DNA vectors were prepared by digesting 600µg 
of the pSKSL-CmR or p-SKSL-KanR plasmid DNAs with 300 units each of the BsaI and 
BstXI restriction enzymes and isolating the larger DNA fragment (around 3kb) by gel 
purification. 150pmol of the gap duplexes were ligated into 100pmol of linearized DNA 
vectors in a large-scale ligation reaction using 60,000 units of T4 DNA ligase in a total 
final volume of 12ml. After ligation, DNA was concentrated by ethanol precipitation and 
then the singly ligated gap plasmids were separated from any unligated DNA vectors and 
multiply ligated DNA products by gel purification (Figure 6), and electroeluted using 
dialysis bags. The isolated gap plasmids were concentrated by ethanol precipitation and 
desalted using an Amicon Ultra-0.5mL Microcon® column (Ultracel 3K Membrane, 
Millipore). The gap plasmids prepared transfected with high efficiency into mouse 
embryonic fibroblast cells. Control gap plasmids without DNA lesions were produced in 
a similar way. 
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Figure 4  Gap plasmids were made by ligating gap duplexes into linear DNA vectors 
A 54mer oligonucleotide with or without a site-specific DNA lesion was produced by 
ligating three shorter oligonucleotides that were phosphorylated at the 5’-end and that 
were annealed to a 34mer scaffold oligo. The 54mer oligo was gel purified (Figure 5) and 
then annealed to two primers to form a gap duplex, which was then ligated into a DNA 
vector to form a double stranded plasmid with a small single stranded gap (Figure 6).   
 
Figure 5  Isolating 54mer oligos containing a site-specific DNA lesion by gel 
purification  
8M urea 12% PAGE. Lane 1 and 2 were loaded with the ligation reaction—ligation of 
three oligonucleotides annealed to 34mer scaffold oligos. Lane 3 was loaded with the 
scaffold DNA only. Lane 4 was loaded with a tracking dye.  
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Figure 6  Gap plasmids produced from a large-scale ligation reaction  
Singly ligated gap plasmids (marked by *) ran at 4kb in 0.8% agarose gel made with 
1xTAE buffer. Lane 2: an aliquot of the large-scale ligation reaction—ligation of gapped 
duplexes into DNA vectors; Lane 3: DNA vectors only. In gel purification of the large-
scale ligation reaction, DNA bands stained with ethidium bromide were visualized under 
short wavelength UV light. Exposure to UV light was kept to minimum to prevent 
formation of pyrimidine dimers. 
 
3.2 8-oxo-G caused a high frequency of mutation 
To determine the mutation frequency of an 8-oxo-G lesion, gap plasmids containing the 
lesion were co-transfected with control gap plasmids without the lesion into mouse 
embryonic fibroblast cells and BL2 cells. The mutation frequency of 8-oxo-G was 
determined by the traditional TLS assay and by the high-throughput TLS assay. 
In the traditional TLS assay, gap plasmids that had been repaired were retrieved from 
mammalian cells and then transformed into E. coli for amplification. The control 
plasmids and lesion plasmids were separated by plating the transformed bacterial cells on 
chloramphenicol plates and on kanamycin plates, respectively. Isolated bacterial colonies 
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arising on the plates were grew in starter cultures and the plasmid DNAs were extracted 
and sent for sequencing. In the high-throughput TLS assay, the gap regions of the 
plasmids retrieved from mammalian cells were amplified by PCR and then sequenced; 
the control plasmids and lesion plasmids were separated based on a three-nucleotide 
difference in their sequence.  
In the traditional TLS assay, the mutation probability of 8-oxo-G was 64 out of 174 
sequences analyzed (36.8%) for MEF cells, and 41 out of 182 sequences analyzed 
(22.5%) for BL2 cells. There were no mutations across from a regular G nucleotide in the 
control plasmids, where 60 control plasmid sequences were analyzed for the MEF cell 
type and for the BL2 cell type, respectively.   
In the high-throughput TLS assay, the mutation frequency of 8-oxo-G or that of a regular 
G nucleotide was the same between MEF cells and BL2 cells. The mutation frequency of 
8-oxo-G was 91% from a total of 319,777 reads analyzed (279,650 reads for MEF cells 
and 40,127 reads for BL2 cells), and that of a regular G nucleotide was 1.6% from a total 
of 541,965 reads analyzed (461,711 reads for MEF cells and 80,254 reads for BL2 cells). 
The background error rate determined as the average of three positive control 
experiments where a fully double stranded plasmid with known sequence was used as 
template in PCR reactions was 0.09%.  
 
3.3 Almost all the mutations caused by 8-oxo-G were C->A 
substitutions 
The mutation spectrum of 8-oxo-G was determined by the traditional TLS assay and by 
the high-throughput TLS assay. Most of the mutations formed across from 8-oxo-G were 
C->A substitutions. In the traditional TLS assay, 93% of mutations (60/64 sequences) 
opposite to the lesion transfected into MEF cells were C->A substitutions, 5% (3/64 
sequences) were C->G substitutions and 2% (1/64 sequences) were C->T substitutions; 
all of the mutations opposite to the lesion transfected into BL2 cells were C->A 
substitutions (38/38 sequences).  
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In the high-throughput TLS assay, 99% of all the mutations across from 8-oxo-G were C-
>A substitutions and only 1% were C->G substitutions (Figure 7). Furthermore, principal 
component analysis of the NGS data shows that, first of all, reads of the control plasmids 
and reads of the lesion plasmids are highly separable based on their nucleotide 
compositions at the position of the DNA lesion (Figure 8); second, the major difference 
between the control plasmid and the lesion plasmid is in the frequency of C->A 
substitutions;  third, change in the variable C (inserted against a regular nucleotide G) in 
the control plasmids is linearly correlated to changes in the variables A and G (inserted 
opposite to 8-oxo-G) in the lesion plasmids at different proportions (Figure 8). The 
variable C is weakly correlated to the variable T and uncorrelated to the variable deletion 
(Figure 8). Principal component analysis indicates that 8-oxo-G caused purine bases, 
mostly A to be incorporated thus producing transverion mutations.  
 
Figure 7  Mutation frequency and mutation profile of 8-oxo-G in mammalian cells.  
Results of the high-throughput TLS assay show that while C was correctly inserted to a 
regular G nucleotide in the control plasmids, A was misincorporated against 8-oxo-G in 
the lesion plasmids and the mutation frequency of 8-oxo-G was 91%. 541,965 reads were 
analyzed for the control plasmids and 319,777 reads were analyzed for the lesion 
plasmids. 
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Figure 8  Biplot generated from principal component analysis of the 8-oxo-G data 
Principal component analysis (PCA) reduces a high dimensional or multivariate dataset 
into a smaller number of linearly uncorrelated variables called principal components 
through orthogonal transformation of the data. The transformation is defined in such a 
way that the first principal component contains the largest possible variance and 
subsequent principal components contain the largest possible variance under the 
constraint that they are uncorrelated to the previous principal components (Aitchison, 
2003). Through PCA the data is placed in a new dimension and is deconstructed into 
eigenvectors and eigenvalues that form the principal components. Eigenvectors and 
values exist in pairs with the eigenvector indicating the direction and the eigenvalue 
indicating the spread of the data in that direction. In simpler terms, PCA reveals the 
underlying structure of the data and divides the variance of the data into directions that 
are perpendicular or principal components that are uncorrelated to each other. A biplot 
displays experimental observations and variables of an experiment on the same plot. Each 
point in the biplot is data of a transfection experiment. The raw experimental data was 
converted into compositional data by first taking log-ratios and then applying center log 
transformation (clr). PCA does not lose the relative scaling of the original variables. In 
the 8-oxo-G study, reads of the control plasmids are well separated from reads of the 
lesion plasmids along principal component one that accounts for 88.4±2.76% of total 
variance of the data. This proves that constructions of the control and the lesion double 
stranded gap plasmids were successful. While the magnitude of composition vectors 
shows the relative proportion of variables, the direction of composition vectors shows the 
correlation among different variables. Data points for the control plasmids (blue dots) are 
largely driven by C incorporated across from a regular G nucleotide and those for the 
lesion plasmids (red dots) are driven by A incorporated against 8-oxo-G. Because a 
change in the variable C is highly correlated to changes in the variables A and G, 8-oxo-
G caused transversion mutations.  
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3.4 There was no apparent biological function of Pol iota in the 
bypass of 8-oxo-G 
Because 8-oxo-G is a very abundant and highly mutagenic DNA lesion (van Loon et al., 
2010), DNA polymerases that can correctly bypass the lesion are biologically important. 
Pol iota is one of the most error-prone DNA polymerases in eukaryotes (Tissier et al., 
2000; Zhang et al., 2000a; Kirouac and Ling, 2011b; Makarova and Kulbachinskiy, 
2012). Previous structural findings demonstrated that Pol iota correctly bypasses 8-oxo-G 
in vitro, thus pointing to a plausible biological function of the DNA polymerase (Kirouac 
and Ling, 2011a).  
To investigate the function of Pol iota in the bypass of 8-oxo-G in mammalian cells, I 
used both the traditional TLS assay and the high-throughput TLS assay. For each assay 
the mutation frequency of 8-oxo-G of a POLI wild type cell line was compared to that of 
a POLI-deficient cell line to deduce Pol iota’s function. In the traditional TLS assay, the 
mutation probability of 8-oxo-G was 33 out of 89 sequences analyzed (37%) for the MEF 
POLI wild type cell line and 31 out of 85 sequences analyzed (37%) for the MEF POLI(-
/-) cell line, so Pol iota did not have an effect on bypassing the lesion in MEF cells (P-
value=1, Fisher’s Exact Test, α=0.05). Also in the traditional TLS assay, the mutation 
probability of 8-oxo-G was 17 out of 93 sequences analyzed (18%) in the BL2 wild type 
cell line and 24 out of 89 sequences analyzed (27%) in the BL2 POLI(-/-) cell line. Pol 
iota also did not play a role in the correct bypass of the lesion in BL2 cells (P-
value=0.2139, Fisher’s Exact Test, α=0.05).  
In the high-throughput TLS assay, there was no difference in the mutation frequency of 
8-oxo-G between the MEF POLI(+/+) wild type cell line and the MEF POLI(-/-) cell line 
nor between the BL2 wild type cell line and the BL2 POLI(-/-) cell line. Therefore, it was 
not likely that Pol iota bypassed 8-oxo-G in mammalian cells. The reason for this result 
could be that the function of Pol iota was redundant with those of other DNA 
polymerases and that Pol iota’s activity was minor compared to those of other DNA 
polymerases so its effect could not be detected in mammalian cells.  
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3.5 Pol eta correctly bypassed 8-oxo-G in vivo  
To determine the functions of Pol iota, Pol eta, Pol kappa, Rev1 and Rev3L on the bypass 
of an 8-oxo-G lesion in mammalian cells, I used the high-throughput TLS assay that 
incorporated the use of Next Generation Sequencing. The high-throughput TLS assay 
shows that Pol eta, among the five translesion DNA polymerases tested correctly 
bypassed 8-oxo-G in vivo. 
To deduce the function of Pol eta, I compared the mutation frequency of 8-oxo-G 
between the MEF POLH(+/+) cell line and the MEF POLH(-/-) cell line, where there 
were nine transfection experiments set up for each cell line. Similarly, to deduce the 
function of Pol kappa, I compared between the MEF POLK(+/+) cell line and the MEF 
POLK(-/-) cell line; to deduce the function of Rev1, I compared between the MEF 
REV1(+/+) cell line and the MEF REV1(-/-) cell line. To deduce the function of Rev3L, I 
compared the 3(+)6 REV3L(+/lox) cell line to each of the 4(-)5 and 4(-)11 cell lines that 
have the genotype REV3L(-/lox); and compared the B2 REV3L(+/+) P53(-/-) cell line to 
each of the B4(-)9 and B4(-)18 cell lines that have the genotype REV3L(-/-) P53(-/-). To 
uncover synergistic effects of the translesion DNA polymerases, I compared each of the 
POLI(+/+), POLH(+/+) and POLK(+/+) wild type cell lines to the two double knockout 
cell lines with the genotypes POLH(-/-)POLI(-/-) and POLK(-/-) POLI(-/-), respectively. 
Moreover, I compared each of the POLI(-/-), POLH(-/-) and POLK(-/-) single knockout 
cell lines to the two triple knockout cell lines named 2091 and 2095, respectively, that 
have the genotype POLH(-/-)POLI(-/-)POLK(-/-). The reader may refer to Appendix E 
for a list of all the cell lines compared in the high-throughput TLS assay.  
I focused on analyzing the frequency of C->A substitutions across from 8-oxo-G because 
the frequencies of C->G and C->T substitutions were negligible. When processing the 
NGS data, I took the within-sample ratio A to C—the proportion of reads with A to those 
with C for a given transfection experiment. This normalized the data to one and cancelled 
out any experimental errors. Then the A/C ratio was log2 transformed to express the 
proportion of reads with A to those with C as fold changes. The log2 transformed A to C 
ratios of nine biological replicates of a cell line were compared to those of the nine 
biological replicates of the other cell line by the Wilcoxon Rank Sum Test. I used this 
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statistical test because it does not make assumption about the data distribution. The 
Wilcox Rank Sum Test evaluates the likelihood that the median of the nine log2(A/C) 
ratios of a wild type cell line and that of the nine log2(A/C) ratios of its isogenic mutant 
cell line were from two different populations. In my case, the test is interpreted as the 
probability that the translesion DNA polymerase(s) in question, which is the only 
difference between the two isogenic cell lines compared, affected the mutation frequency 
of 8-oxo-G. P-values calculated by Wilcox Rank Sum Tests were adjusted by the 
Benjamini-Hochberg method (Benjamini and Hochberg, 1995) to keep Type I error in 
check. The chance of falsely rejecting a null hypothesis is one in twenty when alpha of P-
value is set at 0.05, but when the number of statistical tests performed increases, so is the 
likelihood of making false positive inferences. Benjamini-Hochberg (BH) method 
controls for false positive findings of a study that involves multiple comparisons by 
scaling P-values, so the overall false discovery rate (the ratio of the false positives to true 
positives) of the study is kept low, say at 5% when alpha of the BH-adjusted P-value is 
chosen at 0.05. Where the adjusted P-value was less than 0.05, the difference between 
two isogenic cell lines was deemed statistically significant and the effect size (Cohen’s d) 
and its 95% confidence interval (C. I.) were calculated. Cohen’s d expressed the 
difference in mutation frequency of 8-oxo-G between two isogenic cell lines in units of 
standard deviation. An effect size of 0.6 or greater is considered large by convention.  
The 8-oxo-G study and bypass of the DNA lesion by five translesion DNA polymerases 
took up 9% of the total sequencing capacity. The number of reads obtained for each 
transfection experiment is shown in Figure 9. The most significant finding of the high-
throughput study is that Pol eta correctly bypassed 8-oxo-G. Compared to the MEF 
POLH(+/+) cell line, knocking out the POLH gene alone or knocking out the POLH gene 
along with the POLI gene led to more frequent C->A substitutions across from an 8-oxo-
G lesion but not across from a regular G nucleotide (Figure 10).  
38 
 
 
 
Figure 9  Reads obtained for every transfection experiment in the 8-oxo-G study 
The number of reads for the control plasmid and that for the lesion plasmid are shown for 
every transfection experiment in the 8-oxo-G study (see Appendix F for raw data). For a 
given DNA sample extracted from mammalian cells, the control plasmids and the lesion 
plasmids were amplified in the same PCR reaction (for a total of 25 cycles) and thus their 
reads were labelled with the same barcodes; the reads were split based on a three 
nucleotide difference in their sequences close to the gap region. Data for a total of 192 
transfection experiments are shown. They include nine biological replicates for each of 
the twenty cell lines listed in Table 4, and positive and negative controls done in 
triplicates. Positive control PCR reactions used the control plasmid (without gap) as 
template. There are two types of negative control experiments: in the first type, no 
transfection reagent was added, as a result none of the gap plasmids entered into 
mammalian cells and during alkaline lysis, the gap plasmids were denatured and 
eliminated; in the second type, no DNA template was added in PCR reactions. The 
purpose of this graph is to present raw data for the 8-oxo-G study and to show how the 
NGS capacity was divided among transfection experiments. There are more reads for the 
control plasmid than for the lesion plasmid, indicating that the control plasmid is filled 
more efficiently than the lesion plasmid in mammalian cells; this point will be examined 
in more detail in Section 3.12. 
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Figure 10  The role of POLH on the bypass of 8-oxo-G 
Knocking out the POLH gene alone or knocking out the POLH gene along with the POLI 
gene led to more frequent C->A substitutions. The forest plot shows the effect size and 
the Benjamini-Hochberg (BH) adjusted P-value for comparisons made between the 
POLH(+/+) wild type cell line and each of the POLH(-/-) single knockout and the 
POLH(-/-) POLI(-/-) double knockout (DKO) cell lines.  
 
Besides Pol eta, another translesion DNA polymerase Rev3L correctly bypassed 8-oxo-G 
lesion in one of the four pairs of REV3L cell lines analyzed. Knocking out the REV3L 
gene in a P53 null genetic background resulted in more frequent C->A substitutions 
against an 8-oxo-G lesion but not against a regular G nucleotide (Table 6). 
Table 6  The effect of REV3L on the bypass of 8-oxo-G  
Cell lines (N=9 groups)   Adjusted  
P-value 
Cohen’s 
d  
95% C. I.  
REV3L(+/+) P53(-/-) versus REV3L(-/-) P53(-/-)  
Nick name: B2 versus B4(-)18 
0.023 -2.05 -3.38 to -0.71 
 
Pol kappa and Rev1 had no effects on bypassing 8-oxo-G. Results were validated by the 
NGS data sequenced from the opposite direction (see Appendix A).  
Given that the mutation frequency of 8-oxo-G was found to be 91% in the high-
throughput TLS assay, the finding that Pol eta was the major DNA polymerase in mouse 
embryonic fibroblasts to correctly bypass the lesion is biologically important. Efficient 
and accurate replication of 8-oxo-G by the yeast Pol eta and the human Pol eta have been 
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reported, whereas the role of Rev3L in the tolerance of 8-oxo-G has not been 
characterized.  
 
3.6 The mutation frequency of Pt-GG was similar to that of 
regular GG dinucleotides 
To determine the mutation rate of Pt-GG I used both the traditional TLS assay and the 
high-throughput TLS assay. Gap plasmids containing Pt-GG lesions were co-transfected 
with control gap plasmids without lesions into mouse embryonic fibroblast cells. In the 
traditional TLS assay, gap plasmids that had been repaired in mammalian cells were 
amplified by E. coli and then sequenced. The average mutation probability of Pt-GG was 
19 out of 110 sequences analyzed (17.3%) for the first insertion step, 6 out of 110 
sequences analyzed (5.4%) for the second insertion step, and overall, 25 out of 110 
sequences analyzed (22.7%). There were no mutations across from regular GG 
dinucleotides in the control plasmids from a total of 35 sequences analyzed.  
In the high-throughput TLS assay, the gap region of the plasmids that had been repaired 
in mammalian cells were amplified by PCR. The mutation frequency of Pt-GG was 
21,520 reads out of 4,491,510 reads analyzed (4.79x10-3) and that of regular GG 
dinucleotides was 38,212 reads out of 5,901,558 reads analyzed (6.47x10-3). The 
experimental error rates were 2.05x10-3 for the lesion plasmids (Table 7) and 2.65x10-3 
for the control plasmids (Table 8) determined from positive control experiments. The 
mutation frequency of Pt-GG was similar to that of a regular GG dinucleotides and was 
equal to two times the background error rate of the experiment.  
Table 7  Determining the background error rate for amplifying Pt-GG lesion 
plasmids. 
Positive PCR reactions for 
Pt-GG control plasmids 
Total reads obtained for 
the sample 
Number of reads 
containing errors across 
from GG dinucleotides 
L24R16 25996 65 
L24R17 20242 36 
L24R18 25642 48 
Average error rate  0.00205 
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Table 8  Determining the background error rate for amplifying Pt-GG control 
plasmids.  
Positive PCR reactions for 
Pt-GG control plasmids 
Total reads obtained for 
the sample 
No. of reads containing 
errors across from GG 
dinucleotides 
L23R16 46450 127 
L23R17 52032 144 
L23R18 47291 116 
Average error rate  0.002652 
 
3.7 Mutation spectrum of Pt-GG  
To determine what nucleotides were incorporated across from Pt-GG, I used the 
traditional TLS assay and the high-throughput TLS assay. The most abundant mutation 
arising from Pt-GG lesion was CC->AC substitution. In the traditional TLS assay, most 
of the mutations were CC->AC substitutions: 19 out of 25 sequences that have mutations 
had A mis-inserted at the first insertion step to the DNA lesion, the other 6 sequences 
have mutation at the second insertion step (see Table C-2, Figure C-1 and C-2 in 
Appendix C). In the high-throughput TLS assay, among the 21,520 reads that have 
mutations across from the Pt-GG lesion, 50% are CC->AC substitutions, 12% are CC-
>TC substitutions (Figure 11). Interestingly, in the control plasmids among the 38,212 
reads that have mutations, close to 70% have a single nucleotide deletion at one of the 
two ‘G’ positions; while in the lesion plasmids, only 15% of the reads with mutations 
have a single nucleotide deletion (Figure 11). Compare the mutation spectrum of Pt-GG 
to that of GG, there are large increases in the proportions of reads with CC->AC, AT, AA 
substitutions, small increases in the proportions of reads with CC->TC, CT, CA 
substitutions (Figure 11) and a small decrease in the proportion of reads with double base 
deletions.   
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Figure 11  Mutation spectrums across from Pt-GG lesion and GG dinucleotides in 
mammalian cells 
Mutations across from GG dinucleotides in the control plasmids and Pt-GG in the lesion 
plasmids were measured by the high-throughput TLS assay. The mutation spectrums are 
derived from 38,212 reads of the control plasmids and 21,520 reads of the lesion 
plasmids. In the legend, both ‘A’ and ‘C’ denote a single nucleotide deletion at one of the 
two nucleotide positions of GG or Pt-GG. ‘dd’ stands for double base deletion. 70% of 
the mutations found opposite to GG in the control plasmids are a single nucleotide 
deletion. 65% of the mutations caused by Pt-GG are mis-incorporations of A at the first 
insertion step with or without a mutation at the second insertion step. Incorporations of 
two purine bases to the Pt-GG lesion are rare; CC->AG and CC->AA substitutions across 
from the lesion are much less favored compared to other types of mutations and CC->GA 
and CC->GG substitutions are not found.  
 
Despite their similar mutation frequencies, Pt-GG and the regular GG dinucleotides have 
different mutation patterns. Principal component analysis of the NGS data shows that the 
mutation spectrum of GG in the control plasmids and that of Pt-GG in the lesion plasmids 
are separable (Figure 12A). The length of a composition vector in Figure 12B indicates 
the relative proportion of change in a variable. For example, compared to the GG 
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dinucleotides, Pt-GG causes a large decrease in the frequency of deletions (both a single 
nucleotide deletion and a double base deletion) and large increases in the frequencies of 
mutations CC->AC, AT, AA and AG. The variables AC, AT and AA that form a cluster 
in Figure 12B could be interpreted as being produced by the same molecular mechanism. 
In other words, the mutations CC->AC, AT and AA could be produced by the same DNA 
polymerase or DNA polymerases recruited by a common pathway.   
 
 
Figure 12  Biplot generated from principal component analysis of the Pt-GG data 
Principal component analysis (PCA) reveals the underlying structure of a compositional 
multivariate dataset by reducing its complexity. PCA highlights those variables that 
explain the most variance in the data. Principal Component 1 of the biplot, the x-axis 
explains 43±1.52% of the total variance in the data and Principal Component 2, the y-axis 
explains 10±0.73% of the total variance in the data. A) Each point represents data from a 
transfection experiment. Mutation profiles opposite to ‘GG’ (blue dots) are separable 
from those opposite to Pt-GG (red dots). This indicates that constructions of the control 
plasmids and the lesion plasmids for the Pt-GG study were successful. B) The same 
biplot as shown in A) with composition vectors only. Changes in the variables ‘C’ and 
‘dd’ of the control plasmids are correlated to changes in the variables ‘AC’, ‘AT’, ‘AA’ 
and ‘AG’ of the lesion plasmids. The AC, AT, AA variants are highly correlated because 
the distance between the tips of the rays is small. ‘Clr.’ stands for centered log-ratio 
transformation. ‘dd’ stands for double deletion mutation. The biplots were generated by 
the CoDaPack software (Comas-Cufi and Thió-Henestrosa, 2011). 
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3.8 The role of Pol eta by itself in the bypass of Pt-GG in vivo 
Pt-GG is a major type of cisplatin-DNA adducts found in cancer patients treated with the 
drug cisplatin (Cepeda et al., 2007; Fichtinger-Schepman et al., 1987; Jung and Lippard, 
2007). Pt-GG is considered a bulky DNA lesion because it involves crosslinking of two 
neighboring purines. Due to its large size Pt-GG is thought to be highly blocking to DNA 
replication and is thought to be largely responsible for the drug action of cisplatin 
(Vaisman et al., 2000; Chijiwa et al., 2010). DNA polymerases with the abilities to 
bypass Pt-GG are undesirable in chemotherapy, because their up-regulations are believed 
to increase drug resistance to cisplatin. My aim is to identify translesion DNA 
polymerases that can bypass the Pt-GG lesion because presumably, inactivating these 
DNA polymerases could benefit cancer treatment. 
Recently, it has been shown that Pol eta correctly bypasses Pt-GG in vitro (Ummat et al., 
2012; Zhao et al., 2012). To investigate whether Pol eta has a similar function in 
mammalian cells, I used the traditional TLS assay and the high-throughput TLS assay to 
deduce the biological function of Pol eta. Gap plasmids containing a site-specific Pt-GG 
lesion were co-transfected with control gap plasmids without the lesion into a pair of 
isogenic MEF cell lines with the genotypes POLH(+/+) and POLH(-/-), respectively.  
In the traditional TLS assay, the mutation probability of Pt-GG was 4 out of 29 sequences 
analyzed (14%) in the MEF POLH(+/+) cell line and 10 out of 28 sequences analyzed 
(36%) in the MEF POLH(-/-) cell line. Notably, the incidence of C->A substitution at the 
first insertion step increased by three times when the POLH gene was knocked out and 
that at the second insertion step was unaffected (Appendix C, Figures C-6). This suggests 
that Pol eta correctly bypassed Pt-GG at the first insertion step (P-value=0.0411, Fisher’s 
Exact Test, α=0.05).  
In the high-throughput TLS assay, the mutation frequency of Pt-GG was the same in the 
MEF POLH(+/+) cell line and in the MEF POLH(-/-) cell line, so Pol eta’s effect on 
bypassing Pt-GG was not detected. Using the double and triple knockout cell lines, 
however, it could be inferred that Pol eta and Pol iota together promoted CC->AC and 
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CC->AT substitutions across from the lesion (Section 3.11), so Pol eta bypassed Pt-GG 
in an error-prone manner in vivo.  
The function of Pol eta deduced from the traditional TLS assay was supportive of recent 
structural reports (Ummat et al., 2012; Zhao et al., 2012), but it was not confirmed by the 
high-throughput TLS assay. However, an earlier structural study has shown that Pol eta 
incorporates the correct dCTP at the first insertion step to Pt-GG but it cannot incorporate 
any nucleotides in the second insertion step to the lesion in vitro; therefore, Pol eta cannot 
carry out translesion synthesis of Pt-GG (Chijiwa et al., 2010).  This conclusion is 
consistent with my finding of Pol eta’s cellular function in the high-throughput TLS 
assay.  
 
3.9 The role of Pol iota by itself in the bypass of Pt-GG in vivo 
The POLI gene arises from an ancestral gene duplication of the POLH gene. To 
determine if Pol iota could bypass Pt-GG in vivo, I used the traditional TLS assay and the 
high-throughput TLS assay to deduce the biological function of Pol iota in mammalian 
cells. Lesion gap plasmids containing a Pt-GG lesion were co-transfected with control 
gap plasmids without the lesion into a pair of isogenic MEF cell lines with the genotypes 
POLI(+/+) and POLI(-/-), respectively. 
In the traditional TLS assay, the mutation probability of Pt-GG was 7 out of 29 sequences 
analyzed (24%) in the MEF POLI(+/+) cell line and 4 out of 24 sequences analyzed 
(16.5%) in the MEF POLI(-/-) cell line. Knocking out the POLI gene did not affect the 
probability of mutation at the first insertion step (P-value=1, Fisher’s Exact Test, 
α=0.05), nor that at the second insertion step (P-value=0.49, Fisher’s Exact Test, α=0.05). 
Therefore, Pol iota did not have any effect on bypassing the Pt-GG lesion.  
In the high-throughput TLS assay, I also could not detect the effect of Pol iota between 
the MEF POLI(+/+) cell line and the MEF POLI(-/-) cell line.  
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In the traditional TLS assay, while Pol eta inserted the correct C at the first insertion step, 
Pol iota had no effect. In the high-throughput assay, I could not detect the biological 
function of Pol iota nor that of Pol eta by comparing their wild type cell line to their 
respective isogenic single knockout cell line. In Section 3.11, I detected effects of 
knocking out both the POLI gene and the POLH gene using double- and triple-knockout 
MEF cell lines (Figure 15).  
 
3.10 Rev3L and Rev1 bypassed Pt-GG in mammalian cells  
Rev3L is the catalytic subunit of Pol zeta, a B-family DNA polymerase. It has been 
shown that Rev3L and Rev1 functionally interact in translesion synthesis with Rev1 
acting as a scaffold protein to recruit Rev3L via an interaction with Rev7, the accessory 
subunit of Pol zeta (Murakumo et al., 2001; Kikuchi et al., 2012). Knocking down 
REV3L or REV1 sensitizes mammalian cells to cisplatin (Doles et al., 2010; Xie et al., 
2010). To determine if Rev3L and Rev1 played any roles in the bypass of the Pt-GG 
lesion in mammalian cells, I used the high-throughput TLS assay.  
The high-throughput TLS assay showed that Rev3L and Rev1 bypassed Pt-GG in vivo by 
producing mutations. Lesion gap plasmids containing a Pt-GG lesion were co-transfected 
with control gap plasmids without the lesion into pairs of isogenic MEF cell lines. To 
deduce the cellular function of Rev3L, the frequencies of CC->AC, CC->TC, CC->AA 
and CC->AT substitutions across from the Pt-GG lesion were compared between the 
3(+)6 REV3L(+/lox) Cre cell line and each of the 4(-)5 and 4(-)11 cell lines with the 
genotype REV3L(-/lox) Cre, and between the B2 REV3L(+/+) P53(-/-) cell line and each 
of the B4(-)9 and B4(-)18 cell lines with the genotype REV3L(-/-) P53(-/-). To deduce the 
function of Rev1, mutation frequencies of Pt-GG of the MEF REV1(+/+) cell line were 
compared to those of the MEF REV1(-/-) cell line. Nine transfection experiments were set 
up for each cell line.  
Gap regions of the control plasmids and lesion plasmids recovered from mammalian cells 
were amplified in separate PCR reactions and sequenced by Next Generation Sequencing. 
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In data analysis, the within-sample ratios AC/CC, TC/CC, AT/CC and AA/CC were 
taken and then log 2 transformed. Each of the ratios log2(AC/CC), log2(TC/CC), 
log2(AT/CC), log2(AA/CC) of a cell line (with nine biological replicates) was compared 
to that of the other cell line (also with nine biological replicates) by the Wilcoxon Rank 
Sum Test. Wilcox Rank Sum Test evaluates the likelihood that the medians of the ratios 
from the two cell lines are from two different populations. P-values calculated by Wilcox 
Rank Sum Tests were adjusted by the Benjamini-Hochberg method to control the false 
discovery rate of the study. Where the adjusted P-value was less than 0.05, meaning that 
the probability of falsely detecting an effect for the study is 5% at most, the difference 
between the cell lines was deemed statistically significant and the effect size (Cohen’s d) 
and its 95% confidence interval were calculated. An effect size of 0.6 or greater is 
considered large by convention. 
The Pt-GG study and bypass of the lesion by five translesion DNA polymerases took up 
86% of the total sequencing capacity. Numbers of reads (for the control and for the lesion 
plasmids) obtained for every transfection experiment are shown in Figure 13.  
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Figure 13  Reads obtained for every transfection experiment in the Pt-GG study 
Number of reads for the control plasmid and number of reads for the lesion plasmid for 
every transfection experiment in the Pt-GG study (see Appendix I for raw data). The 
control plasmids and the lesion plasmids of a transfection experiment were amplified in 
separate PCR reactions for a total of 55 cycles and their reads were sorted by barcodes. 
There are 192 transfection experiments, including nine biological replicates for each of 
the twenty cell lines listed in Table 4 and positive and negative control reactions done in 
triplicates. Positive control PCR reactions used the control plasmid without the gap or the 
lesion plasmid without the lesion and without the gap as DNA template. There are two 
types of negative control experiments: in the first type, no transfection reagent was 
added, so gap plasmids did not enter into mammalian cells. The purpose of this negative 
control experiment is to check that the gap plasmids were effectively removed by alkaline 
lysis. In the second type of negative control, no DNA template was added in the PCR 
reactions.  
 
The mutation frequency of Pt-GG was in the order of 10-3 and was similar to that of a 
regular GG dinucleotides. Rev3L and Rev1 had no effects on bypassing GG in the 
control plasmids but produced mutations opposite to Pt-GG in the lesion plasmids where 
50% of the mutations were CC->AC substitutions. The effect of Rev3L was validated in 
more than one pair of cell lines. Knocking out REV3L or REV1 resulted in less frequent 
CC->AC substitutions (Figure 14). In addition to CC->AC substitutions, knocking out 
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REV3L in a P53 null genetic background resulted in less frequent CC->TC substitutions 
(Table 9). The same results were obtained from NGS data sequenced in the reverse 
direction (Appendix B).  
 
 
Figure 14  Knocking out REV3L or REV1 resulted in less frequent CC->AC 
substitutions across from Pt-GG 
Knocking out the REV3L gene conditionally or in a P53 null genetic background resulted 
in less frequent CC->AC substitutions across from Pt-GG; each result was confirmed in 
two pairs of isogenic cell lines. Knocking out the REV1 gene produced a similar effect as 
knocking out the REV3L gene. Effect sizes and Benjamini Hochberg (BH) adjusted P-
values are shown for the comparisons between isogenic cell lines. 
 
Table 9  Knocking out REV3L resulted in less frequent substitutions of CC->TC 
across from Pt-GG 
Genotypes of cell lines compared  
(N=9 groups) 
Adjusted 
P-value 
Cohen’s 
d 
95% C. I. 
REV3L(+/+) P53(-/-) versus REV3L(-/-) P53(-/-) 
Nicknames: B2 versus B4(-)18 
 
0.0018 2.28 0.88-3.67 
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There is strong support for Rev3L functioning as a major DNA polymerase to bypass Pt-
GG in mammalian cells. It has been reported that cell lines lacking a functional REV3L 
gene are hypersensitive to cisplatin treatment (Zander and Bemark, 2004). A two-
polymerase model based on protein-protein interaction studies suggested that the 
complete bypass of Pt-GG requires Rev3L to act as an extender DNA polymerase, 
preceded by another DNA polymerase inserting a nucleotide at the first insertion step. 
Here I show that knocking out REV3L caused either A or T to be mis-incorporated at the 
first insertion step to a Pt-GG lesion, hence Rev3L can function on its own to bypass the 
lesion.  
Knocking out REV1 produced a similar effect as knocking out REV3L. Rev1 may bypass 
Pt-GG indirectly by acting as a scaffold protein to recruit Rev3L or other translesion 
DNA polymerases. If REV1 and REV3L proteins require each other to function properly 
in translesion synthesis, disrupting either the REV1 or the REV3L gene could entail a 
completely different DNA polymerase to bypass Pt-GG. The ability of Rev1 to bypass Pt-
GG directly has not been studied in vitro. 
 
3.11 Each of Pol kappa and Pol eta associated with Pol iota in the 
bypass of Pt-GG in vivo 
To determine the effects of Pol kappa, Pol iota and Pol eta on the bypass of the Pt-GG 
lesion, I used the high-throughput TLS assay. Although recently structural explanations 
were provided for the correct bypass of Pt-GG at the first insertion step by Pol eta 
(Ummat et al., 2012; Zhao et al., 2012), I did not find any effects of Pol eta, at least not 
by itself, on bypassing the DNA lesion in vivo. My results show that Pol kappa, rather 
than Pol eta bypassed Pt-GG and the bypass was error-prone (Figure 15).  
To deduce the function of Pol kappa, isogenic cell lines with and without the POLK gene 
were compared. The POLK wild type cell line was compared to the POLK(-/-) single 
knockout cell line; the POLI(-/-) cell line was compared to the POLK(-/-) POLI(-/-) 
double knockout cell line; the POLH(-/-) POLI(-/-) cell line (with functional POLK gene) 
was compared to each of the POLH(-/-) POLI(-/-) POLK(-/-) triple knockout cell lines 
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2091 and 2095, respectively (Figure 15). Although in vitro studies have shown that Pol 
kappa cannot bypass a Pt-GG adduct in DNA template (Gerlach et al., 2001), work done 
by Vikash Jha in our lab showed that Pol kappa had some activities in bypassing the 
lesion in vitro (unpublished data). The ability of Pol kappa to bypass Pt-GG was 
functionally redundant to that of Pol iota, because the effect of knocking out Pol kappa 
was only detected in the absence of Pol iota, and vice versa (Figure 15). Knocking out 
Pol kappa and Pol iota together resulted in less frequent CC->AC and CC->AA 
substitutions across from the lesion (Figure 15, Table 10).  
Table 10  Knocking out POLK and POLI together resulted in less frequent 
substitutions of CC->AA across from Pt-GG 
Genotypes of cell lines compared 
(N=9 groups)  
Adjusted 
P-value 
Cohen’s 
d 
95% C. I. 
POLK wild type vs. POLK(-/-) POLI(-/-) DKO 0.038 2.13 0.77-3.49 
POLI wild type vs. POLK(-/-) POLI(-/-) DKO 0.0018 2.27 0.88-3.66 
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Figure 15 Knocking out POLK in the absence of POLI or knocking out POLH in the 
absence of POLI resulted in less frequent CC->AC substitutions across from Pt-GG 
While the effect of Pol kappa could not be detected between the POLK(+/+) wild type 
cell line and the POLK(-/-) single knockout cell line, knocking out the POLK gene in the 
absence of the POLI gene or vice versa resulted in less frequent CC->AC substitutions. 
Knocking out the POLK gene and the POLI gene together produced less frequent CC-
>AC substitutions. Knocking out the POLH gene and the POLI gene together also 
resulted in less frequent CC->AC substitutions. The function of Pol iota was associated 
with those of Pol kappa and Pol eta in the bypass of Pt-GG.  
 
To deduce the function of Pol eta, isogenic MEF cell lines with and without the POLH 
gene were compared. The POLH(+/+) cell line was compared to the POLH(-/-) single 
knockout cell line and to the POLH(-/-) POLI(-/-) double knockout cell line, respectively. 
The POLK(-/-) cell line (with functional POLH and POLI genes) was compared to each 
of the POLK(-/-) POLI(-/-) POLH(-/-) triple knockout cell lines 2091 and 2095, 
respectively. My result shows that Pol eta and Pol iota together bypassed Pt-GG and 
made CC->AC and CC->AT substitutions (Figure 15, Table 11), suggesting that the two 
DNA polymerases cooperated to bypass the Pt-GG lesion. It has been shown that 
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localization of Pol iota to replication foci is largely dependent on Pol eta and that the C-
terminal 224 amino acids of Pol iota are sufficient for binding to Pol eta (Kannouche et 
al., 2003). It has also been reported that physical and functional interactions of Pol eta 
and Pol iota are mediated by ubiquitin and are dependent on ubiquitination of either of 
the DNA polymerases (McIntyre et al., 2013). 
Table 11  Knocking out POLH and POLI together resulted in less frequent 
substitutions of CC->AT across from Pt-GG 
Genotypes of cell lines compared 
(N=9 groups)  
Adjusted 
P-value 
Cohen’s 
d 
95% C. I. 
POLH wild type vs. POLH(-/-) POLI(-/-) DKO 0.038 1.85 0.56-3.14 
 
Despite the low mutation rate of Pt-GG, which was similar to that of a regular GG 
dinucleotides, several translesion DNA polymerases could be recruited, possibly via 
different pathways to bypass the lesion in mammalian cells. I do not know yet which 
DNA polymerase(s) correctly bypassed Pt-GG in the cell, but it would be interesting to 
find out.  
Since Pt-GG is implicated in blocking DNA replication (Vaisman et al., 2000; Chijiwa et 
al., 2010; Zhao et al., 2012), I would like to determine the bypass efficiency of the DNA 
lesion. In the next section, I present results of the traditional TLS assay, Q-PCR and the 
high-throughput TLS assay for studying translesion synthesis efficiencies of Pt-GG and 
8-oxo-G and in other words, measuring the blocking effects of the DNA lesions.  
 
3.12 Pt-GG and 8-oxo-G had similar blocking effects to DNA 
replication  
In addition to mutagenesis, DNA lesions are replicated less efficiently than regular 
nucleotides. The delay in replicating a DNA lesion relative to a normal nucleotide allows 
recruitment of translesion DNA polymerases to bypass damaged DNA. I speculated that 
the blocking effect of a DNA lesion is directly related to its size. Pt-GG is believed to be 
highly blocking to DNA replication because it involves crosslinking of two adjacent 
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purine bases (Vaisman et al., 2000; Chijiwa et al., 2010); by contrast, 8-oxo-G is believed 
to be less obstructive to DNA replication. (Shibutani et al., 1991; Einolf and Guengerich, 
2001; Avkin and Livneh, 2002; Markkanen et al., 2012) I hypothesized that Pt-GG has a 
larger blocking effect than 8-oxo-G in vivo. 
Studying the blocking effect of a DNA lesion is important because the difference in the 
bypass efficiency of Pt-GG and 8-oxo-G could entail different mechanisms of recruiting 
translesion DNA polymerases. The widespread presence of Pt-GG in patients who are 
treated with cisplatin is thought to kill tumor cells by preventing DNA replication.  
To investigate translesion synthesis efficiencies of 8-oxo-G and Pt-GG in mammalian 
cells, I first used the traditional TLS assay and Q-PCR to study bypass efficiency of 8-
oxo-G in four DNA samples. There I found a discrepancy in the results of the two 
methods (Table 12 and Table 13). Then I used Q-PCR to study the bypass efficiencies of 
8-oxo-G and Pt-GG, respectively, in nine MEF cell lines and validated the results using 
data of Next Generation Sequencing (Table 14 and Table 15).  
In the traditional TLS assay, the translesion synthesis efficiency is estimated by taking 
the ratio of the number of bacterial colonies arising on a kanamycin plate (selecting for 
the lesion plasmids), to that arising on a chloramphenicol plate (selecting for the control 
plasmids). Four DNA samples A, B, C, D extracted from the four cell lines MEF 
POLI(+/+), MEF POLI(-/-), BL2 POLI(+/+), and BL2 POLI(-/-), respectively, were 
transformed into CSH117 electrocompetent cells in triplicates.  Following each 
transformation, undiluted cells were plated in triplicates on kanamycin plates and on 
chloramphenicol plates, and the number of bacterial cells arising on the plates were 
counted. The Kan/Cm ratio was calculated using average numbers of bacterial colonies 
from the three kanamycin plates (Kan) and from the three chloramphenicol plates (Cm). 
Results of the translesion synthesis efficiencies of 8-oxo-G measured from the four DNA 
samples with the traditional TLS assay are shown in Table 12.  
Using the same four DNA samples as above, I measured the number of copies of lesion 
plasmids and that of the control plasmids by Q-PCR and then calculated the Kan/Cm 
ratio for each DNA sample (Table 13). DNA standards and unknown samples were 
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measured in replicates. Q-PCR reactions were set up using 2x EvaGreen qPCR Master 
Mix and ran on the Eppendorf RealPlex Mastercycler instrument. 
 
Table 12  Bypass efficiencies of 8-oxo-G estimated by the traditional TLS assay 
Gap plasmids transfected into mammalian cells were repaired and then recovered by the 
Alkaline Lysis method. The DNA was transformed, in three independently 
transformation experiments into bacteria (CSH117 strain). In the table are numbers of 
bacterial colonies arising on three kanamycin (Kan) plates and on three chloramphenicol 
(Cm) plates when undiluted bacterial cells from each transformation experiment were 
spread. The bypass efficiency of 8-oxo-G (Kan/Cm) is calculated as the ratio of the 
average number of bacterial colonies on the Kan plates to that on the Cm plates. 
  A B C D 
 Plate 3LG188.1 
MEF POLI(+/+) 
3LG188.2 
MEF POLI(-/-) 
3LG102.5 
BL2 POLI(+/+) 
3LG102.6 
BL2 POLI(-/-) 
The 1st 
transformation 
experiment 
Kan 22, 32, 24 26, 28, 24   
Cm 18, 20, 18 12, 26, 18   
Kan/Cm 1.42 1.37   
The 2nd 
transformation 
experiment 
Kan 54, 70, 55 52, 69, 171 26, 24, 20 10, 5, 8 
Cm 25, 24, 38 30, 22, 24 24, 12, 28 4, 5, 8 
Kan/Cm 2.07 2.34 1.09 1.33 
The 3rd 
transformation 
experiment 
Kan 30, 43, 29 79, 86, 86 49, 36, 35 25, 37, 23 
Cm 28, 35, 27 62, 53, 63 41, 24, 49 19, 26, 19 
Kan/Cm 1.13 1.4 1.05 1.32 
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Table 13  Bypass efficiencies of 8-oxo-G of the same DNA samples as in Table 12 
measured by Q-PCR 
Gap plasmids transfected into mammalian cells were repaired and then recovered by the 
Alkaline Lysis method that effectively eliminated any unrepaired plasmids. From the 
DNA sample, the number of copies of control plasmids and the number of copies of 
lesion plasmids were measured by quantitative PCR using standard curves. Ct is the cycle 
threshold number set above the background in a Q-PCR reaction; it is used to determine 
the concentration or the copy number of the plasmids. 
 A B C D 
 3LG188.1 
MEF POLI(+/+) 
3LG188.2 
MEF POLI(-/-) 
3LG102.5 
BL2 POLI(+/+) 
3LG102.6 
BL2 POLI(-/-) 
replicates 1 2 1 2 1 2 1 2 
Ct value, p-Kan 10.74 10.54 14.95 15.19 11.59 11.6 11.75 11.72 
Ct value, p-Cm 11.93 11.55 17.46 17.56 12.96 12.86 12.65 13 
Copy no. p-Kan 4.55E+8 5.34E+8 1.54E+7 1.27E+7 2.30E+8 2.28E+8 2.02E+8 2.07E+8 
Copy no. p-Cm 3.57E+9 4.59E+9 9.39E+7 8.79E+7 1.81E+9 1.94E+9 2.22E+9 1.77E+9 
Kan/Cm ratio 0.13 0.12 0.16 0.14 0.13 0.12 0.09 0.12 
 
The bypass efficiencies of 8-oxo-G measured by the traditional TLS assay exceed one 
and show large variations among repeat transformation experiments ( 
Table 12). Given that the lesion gap plasmids and the control gap plasmids were co-
transfected in equal molar amounts, a Kan/Cm ratio greater than one would indicate that 
the lesion plasmids were repaired more efficiently than the control plasmids and that 8-
oxo-G was replicated more rapidly than a regular G—a result contrary to my expectation. 
Using Q-PCR, however, I found that for the same DNA samples the bypass efficiencies 
of 8-oxo-G were around 0.12 (Table 13), which indicates that for every ten control gap 
plasmids that were filled, one lesion gap plasmid was repaired, or that 8-oxo-G was 
bypassed at about one tenth the rate of a regular nucleotide in cells. Results of the Q-PCR 
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experiments are more reproducible. I believe Q-PCR is a more reliable and accurate 
method than the traditional TLS assay in estimating a DNA lesion’s bypass efficiency.  
Next, I used Q-PCR to determine the translesion synthesis efficiencies of 8-oxo-G and Pt-
GG, respectively, from nine MEF cell lines, and validated the results using the high-
throughput data.  I wanted to know how the bypass efficiencies of 8-oxo-G and Pt-GG 
differ. Furthermore, I asked if the translesion synthesis efficiencies of the lesions were 
influenced by knocking out one, two or three of the DNA polymerase genes POLI, POLK 
and POLH. If Pol iota or Pol kappa or Pol eta was the only DNA polymerase in cells able 
to bypass either of the DNA lesion, inactivating the DNA polymerase should greatly 
reduce the bypass efficiency for that DNA lesion.  
Q-PCR reactions were set up on a 384-well plate using Syber Select Master Mix and ran 
in the ViiA7 instrument as described in Methods. The four DNA samples measured 
previously were not used in this experiment. For each cell line, samples of three 
transfection experiments were measured (Table 14) and three technical replicates were 
set up to measure each sample. Translesion synthesis efficiencies of the same samples in 
Table 14 were also determined and validated using results of the high-throughput TLS 
assay (Table 15), based on the ratio of the number of reads obtained for the lesion 
plasmids to that obtained for the control plasmids for a given transfection experiment 
(Table 15). 
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Table 14  Bypass efficiencies of 8-oxo-G and Pt-GG in nine MEF cell lines measured 
by Q-PCR  
Each Kan/Cm ratio in the table is the number of copies of lesion plasmids to that of 
control plasmids for a transfection experiment and the number shown is the average of 
three technical replicates. 
Genotypes of MEF 
cell lines 
8-oxo-G 
Kan/Cm ratios of three 
biological replicates 
Pt-GG 
Kan/Cm ratios of three 
biological replicates 
1 2 3 1 2 3 
POLI wild type 0.68 0.62 0.9 0.8 0.7 0.67 
POLI(-/-) 2.34 0.9 0.83 0.45 0.68 0.63 
POLH wild type 0.81 0.65 0.65 0.57 0.53 0.51 
POLH(-/-) 0.53 0.67 0.68 0.56 0.53 0.49 
POLK wild type 0.52 0.46 0.50 0.72 0.61 0.57 
POLK(-/-) 0.65 1.20 0.51 0.68 0.85 0.69 
POLH/I DKO 0.54 0.71 0.60 0.56 0.56 0.64 
POLK/I DKO 0.58 0.59 0.54 0.57 0.53 0.68 
2091 POLH/K/I TKO 0.74 0.83 0.72 1.20 0.86 0.85 
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Table 15  Bypass efficiencies of 8-oxo-G and Pt-GG of the same samples as in Table 
14 determined from the NGS data 
Each number is the ratio of the number of reads obtained for the lesion plasmids to that 
obtained for the control plasmids for a transfection experiment. 
Genotypes of MEF 
cell lines 
8-oxo-G 
Kan/Cm ratios of three 
biological replicates 
Pt-GG 
Kan/Cm ratios of three 
biological replicates 
1 2 3 1 2 3 
POLI wild type 0.54 0.61 0.61 1.09 0.95 0.90 
POLI(-/-) 0.75 0.59 0.55 0.54 0.90 0.79 
POLH wild type 0.67 0.63 0.59 0.74 0.80 0.83 
POLH(-/-) 0.58 0.59 0.57 0.74 0.91 0.82 
POLK wild type 0.47 0.47 0.42 1.83 1.61 1.73 
POLK(-/-) 0.59 0.57 0.65 1.37 1.02 1.21 
POLH/I DKO 0.56 0.59 0.55 0.60 0.11 0.61 
POLK/I DKO 0.55 0.59 0.60 0.69 0.66 0.67 
2091 POLH/K/I TKO 0.60 0.65 0.66 0.60 0.80 0.52 
 
Translesion synthesis efficiencies of 8-oxo-G and Pt-GG determined by Q-PCR and by 
the high-throughput TLS assay are in good agreement (Table 14 and Table 15) despite a 
few outliers with values greater than 1. All the data considered there is no statistically 
significant difference between the bypass efficiencies of 8-oxo-G and Pt-GG; the average 
Kan/Cm ratio of either of the two DNA lesions is about 0.6. Knocking out the genes 
POLI, POLK and POLH did not have any effects on the bypass efficiency of 8-oxo-G or 
the bypass efficiency of Pt-GG.  
Even though Pt-GG has been shown to be highly blocking to DNA replication under 
well-defined in vitro conditions, it was not the case in vivo. My results show that the 
blocking effect of Pt-GG was the same as that of 8-oxo-G in mammalian cells. It can be 
reasoned that DNA polymerases accommodated a single base of Pt-GG rather than the 
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cross-linked dimer in catalysis. Since the genotypes of the cell lines did not have any 
effects on the TLS efficiencies of either of the two DNA lesions, the functions of Pol iota, 
Pol kappa and Pol eta were not obligatory for the bypass of 8-oxo-G or Pt-GG in 
mammalian cells. Other DNA polymerases could fill the gap plasmids and bypass the 
DNA lesions.  
Even though Pt-GG presents itself as a major roadblock for certain DNA polymerases in 
vitro, cells have capabilities to bypass this lesion efficiently because multiple DNA 
polymerases could carry out this function in vivo. Pt-GG hindered DNA replication, but 
surprisingly, its blocking effect was comparable to that of 8-oxo-G and was not as severe 
as previously implicated. This suggests that the presence of Pt-GG in DNA is not a major 
contributing factor to the anti-tumor property of cisplatin. On the other hand, 8-oxo-G 
was replicated less efficiently compared to a regular G nucleotide and the lesion’s 
blocking effect was greater than previously considered. The finding that 8-oxo-G and Pt-
GG lesions were bypassed with similar efficiencies in vivo was not expected judging by 
the relative size of the two lesions.  
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Chapter 4  
4 Discussions 
4.1 Traditional TLS assay and high-throughput TLS assay 
revealed totally different results  
Mutation frequencies of 8-oxo-G and Pt-GG were 37% (64/174 sequences) and 22% 
(25/110 sequences), respectively, in MEF cells estimated by the traditional TLS assay, 
and 91% (254,481/279,650 reads) and less than 1% (21,520/4,491,510 reads), 
respectively, in MEF cells estimated by the high-throughput TLS assay. Whereas the 
traditional TLS assay was inconclusive about the role of Pol iota in bypassing 8-oxo-G, 
the high-throughput TLS assay showed that Pol iota did not have an effect. Whereas the 
traditional TLS assay showed that Pol eta correctly bypassed Pt-GG in the first insertion 
step and that Pol iota had no effect in bypassing the DNA lesion, the high-throughput 
TLS assay showed that neither Pol eta nor Pol iota had any effects, but that Pol kappa 
bypassed Pt-GG and the bypass was error-prone. Results of the traditional TLS assay 
show that 8-oxo-G was replicated more efficiently than a regular G nucleotide, which is 
contrary to my expectation. Results of the high-throughput TLS assay on the other hand, 
show that the bypass efficiency of 8-oxo-G and that of Pt-GG were about 0.6 relative to 
regular nucleotides measured by Q-PCR and Next Generation Sequencing. This means 
that each of 8-oxo-G and Pt-GG was replicated at 0.6 times the rate of regular 
nucleotides. I believe the differences in results between the traditional TLS assay and the 
high-throughput TLS assay are due to the use of E. coli in the traditional TLS assay. The 
high-throughput TLS assay is better able to capture mutations made inside mammalian 
cells caused by DNA lesions. 
The high-throughput TLS assay produced more consistent results across transfection 
experiments than the traditional TLS assay. Next Generation Sequencing generated a 
much larger sample size than the traditional TLS assay for each transfection experiment. 
The traditional TLS assay revealed that the mutation frequency of 8-oxo-G was 33% in 
both the MEF POLI(+/+) cell line (33/89 sequences) and the MEF POLI(-/-) cell line 
(31/85 sequences), and was 18% in the BL2 POLI(+/+) cell line (17/93 sequences)and 
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27% in the BL2 POLI(-/-) cell line (24/89 sequences). The high-throughput TLS assay 
showed that the mutation frequency of 8-oxo-G was 91% in all four of the cell lines 
where thousands of sequences were analyzed for each cell line. The difference in 
mutation frequency of a DNA lesion was very subtle in the high-throughput TLS assay 
across all the cell lines, less than 1% for sure. As a result, the high-throughput data must 
be analyzed differently from the data of the traditional TLS assay. The high-throughput 
data were treated as compositional and log-ratio analyses were used to detect differences 
in mutation frequencies of a DNA lesion in pairs of isogenic cell lines. 
The use of E. coli in the traditional TLS assay not only had impact on the mutation 
frequencies of 8-oxo-G and Pt-GG, but also resulted in additional mutations arising in the 
gap region close to the DNA lesion (Appendix C). These mutations were not observed in 
the high-throughput TLS assay so they must have arisen in bacteria. In the high-
throughput assay, a mutation was observed only where across from a DNA lesion. 
Observations from the traditional TLS assay demonstrate that a damaged nucleotide in a 
DNA sequence could, over the course of many rounds of DNA replications and cell 
divisions in bacteria, cause mutations of its neighboring bases. Not realizing that 
mutations in the traditional TLS assay result from multiple events, observations of 
mutations caused by a DNA lesion in bacteria led to the development of a two-
polymerase model for translesion synthesis. In this model, translesion synthesis is divided 
into two steps, insertion to the lesion and extension with each step requiring a different 
error-prone DNA polymerase, because mutations across from and next to a DNA lesion 
were thought to be made by different error-prone DNA polymerases (Prakash and 
Prakash, 2002; Friedberg et al., 2005; McCulloch and Kunkel, 2008; Shachar et al., 
2009). Results of the high-throughput TLS assay show that mutations that were not 
directly opposite to DNA lesions did not result immediately from translesion synthesis, 
thus calling into question the two-polymerase model.  
Results of the high-throughput TLS assay are consistent with polymerase switching 
whereby a translesion DNA polymerase is recruited to specifically insert a nucleotide 
opposite to the lesion. The results are also consistent with having just one translesion 
DNA polymerase filling the entire gap region, because the error rate of a translesion 
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DNA polymerase is 10-2 to 10-4 and the gap region spans only 12 nucleotides. Therefore, 
translesion DNA polymerases play important roles in synthesizing short gaps in DNA 
repairs. 
 
4.2 Several DNA polymerases can bypass 8-oxo-G and Pt-GG in 
cells 
We predicted that Pol iota is the only DNA polymerase to correctly bypass 8-oxo-G in 
vivo, but found instead Pol eta carried this function in mammalian cells. Effects of Pol 
iota were detected in the absence of Pol eta or Pol kappa; therefore, Pol iota together with 
Pol eta and Pol iota together with Pol kappa bypassed 8-oxo-G correctly. In one of the 
four pairs of REV3L cell lines, Rev3L was found to bypass 8-oxo-G correctly.  
Rev3L, Rev1 and Pol kappa bypassed Pt-GG in an error-prone manner in mammalian 
cells. The functions of Rev3L and Rev1 may be associated because Rev1 can act as a 
scaffold protein to recruit Rev3L (Acharya et al., 2006; Hashimoto et al., 2012; Kikuchi 
et al., 2012).  The biological function of Pol kappa was redundant with that of Pol iota 
because Pol kappa’s effect was detected only in the absence of Pol iota, and vice versa. 
Among Pol kappa, Pol iota and Pol eta, Pol kappa was the major DNA polymerase to 
bypass Pt-GG, and contrary to previous reports (Ummat et al., 2012; Zhao et al., 2012), 
Pol eta did not have a major role in bypassing the Pt-GG lesion. It was also reported that 
Pol eta could not carry out translesion synthesis of Pt-GG (Chijiwa et al., 2010), because 
in the structural study Pol eta could not incorporate nucleotides at the second insertion 
step of the DNA lesion. 
 
4.3 Properties of 8-oxo-G and Pt-GG in mammalian cells 
In the beginning of the study, I thought that Pt-GG but not 8-oxo-G blocks DNA 
replication because Pt-GG is a more bulky DNA lesion. While previous studies show that 
Pt-GG cannot be readily bypassed by many DNA polymerases in vitro (Vaisman et al., 
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2000; Chijiwa et al., 2010), my results show that Pt-GG was bypassed with the same 
efficiency as 8-oxo-G in mammalian cells.  
The mutation rate of 8-oxo-G (9.1x10-1) was two orders of magnitudes higher than that of 
Pt-GG (4.7x10-3) in vivo. The large difference in mutation rate reflected the difference in 
intrinsic mutagenic properties of the DNA lesions. Pt-GG is less prone to base mis-
insertions because DNA polymerases allow some flexibility in DNA backbone and are 
able to traverse the slight bent introduced by the intrastrand cisplatin crosslink when 
incorporating nucleotides to Pt-GG. For the 8-oxo-G lesion, an additional oxygen atom in 
a guanine base alters its charge and therefore resulted in a high frequency of A mis-
incorporation against 8-oxo-G. The large difference in mutation rate of the two DNA 
lesions could also be due to different DNA repair mechanisms involved in removing the 
DNA lesions. Perhaps the mechanism for removing Pt-GG lesions acted sooner than that 
for 8-oxo-G lesions. While 8-oxo-G is largely removed by base excision repair pathway 
through recognition of the lesion by the DNA glycosylase enzyme OGG1, Pt-GG is 
largely removed by nucleotide excision pathway that recognizes the distortion in local 
DNA structure caused by the DNA lesion. The basis for recognizing the 8-oxo-G lesion 
relies less on DNA geometry and possibly, more on charge and that for recognizing the 
Pt-GG lesion rests on deviation in its local DNA structure. This could entail different 
mechanisms (recruitment of different protein ensembles), thus different timings at which 
the lesions were repaired. Clearly, 8-oxo-G is the more harmful of the two DNA lesions. 
The high incidence of transversion mutations arising from 8-oxo-G underlines the 
importance of DNA repair to remove this lesion before DNA replication.  
Pt-GG caused very few mutations: its mutation rate was only two times the background 
error rate in the NGS study. All of Pol iota, Pol kappa, Pol eta, Rev1 and Rev3L were 
error-prone to the lesion. I do not know which DNA polymerase(s) bypassed Pt-GG 
correctly in vivo, but it would be important to find out, because inactivating those DNA 
polymerases should reduce drug resistance to cisplatin in chemotherapy.  
Then a question arises: what makes the cisplatin drug effective to kill cancerous cells 
since Pt-GG, a major species of cisplatin-DNA adducts, did not block DNA replication 
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more than 8-oxo-G, and 8-oxo-G is an abundant DNA lesion. I argue that cisplatin’s drug 
effect does not depend on Pt-GG to block DNA replication, at least not by Pt-GG alone, 
and the toxicity of cisplatin to tumor cells have other explanations (Cepeda et al., 2007; 
Jung and Lippard, 2007). For one, it is conceivable that inter-strand cisplatin DNA 
adducts would stall normal DNA replication. Also, cisplatin-DNA adducts attract binding 
of the nonhistone High Mobility Group (HMG)-family of proteins that alter chromatin 
structures (Rabik and Dolan, 2007); HMG proteins bound to Pt-GG lesions or other 
cisplatin-DNA adducts could stall DNA replication (Rabik and Dolan, 2007). Cisplatin 
also modifies amino acid residues of cytoplasmic and nuclear proteins (Woźniak and 
Błasiak, 2002) and HMG proteins bound to cisplatin modified proteins could disrupt the 
cell’s internal architecture (Woźniak and Błasiak, 2002). 
 
4.4 Limitations on using cell lines as models in the high-
throughput TLS assay to study protein functions 
There are limitations on using mammalian cell lines with specific gene knockouts to 
study functions of translesion DNA polymerases. First, even with the Next Generation 
Sequencing technology that produces thousands of reads for each cell line, the biological 
effect of a single gene is elusive because only subtle differences in mutation frequencies 
could be detected between isogenic cell lines. Second, results of the high-throughput TLS 
assay are indirect as I do not know which DNA polymerase(s) actually fill the gap 
plasmids in cells. The best I could do is to acknowledge a probability that the translesion 
DNA polymerase in question has taken action. I do not know if the proteins are expressed 
in wild type cells, since I could not detect Pol iota, Pol eta and Pol kappa in Western 
Blotting experiments using monoclonal primary antibodies (results not shown). Labs that 
generated the knockout cell lines used in this project (Table 4) have confirmed the 
genotypes of the cell lines by PCR and checked the expressions of the DNA polymerases 
by Western Blotting. Third, I overloaded the cells or stressed the system with exogenous 
DNA in transfection, which might cause the cells to not behave as they would under 
normal physiological conditions. Forth, in analyzing the NGS data I made exhaustive 
comparisons between cell lines to deduce the functions of translesion DNA polymerases. 
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The many t-tests performed greatly increases the chance of committing Type 1 error—
detecting an effect for a translesion DNA polymerase when in fact it does not have any. 
Type 1 error cannot be eliminated even with P-value adjustment: the Benjamini 
Hochberg method was chosen because it is less conservative than the Bonferroni 
correction. For all of these reasons, my findings on the biological functions of translesion 
DNA polymerases in the high-throughput TLS assay are preliminary and would need to 
be validated by other means, such as in vitro assays using purified proteins. 
 
4.5 The high-throughput TLS assay generated new hypotheses for 
further testing 
The high-throughput TLS assay is a valuable tool for generating new hypotheses. From 
my results, Pol eta had a major role in correctly bypassing 8-oxo-G in mammalian cells. 
This finding is supported by other reports that study the kinetics (Haracska et al., 2000; 
Washington et al., 2001), X-ray crystal structures (Silverstein et al., 2010), and genetics 
(Rodriguez et al., 2013) of the yeast Pol eta in bypassing 8-oxo-G.  
Rev3L bypassed Pt-GG in all four pairs of the REV3L cell lines analyzed (Figure 14). 
This finding is supported by previous reports that showed that Rev3L confers chemo-
resistance to cisplatin (Wang et al., 2009) and REV3L-deficient cells are sensitive to 
cisplatin (Sonoda et al., 2003; Zander and Bemark, 2004; Doles et al., 2010). Knocking 
out REV1 produced a similar effect as knocking out REV3L. Rev1 bypassed Pt-GG, and 
Rev1 may function on its own or recruit Rev3L to bypass the DNA lesion. Compared to 
Pol eta and Pol iota, Pol kappa had a greater activity in bypassing Pt-GG in vivo. Pol 
kappa’s biological function was detected in the absence of Pol iota, and vice versa, 
suggesting their functions were either complementary or redundant. Pol eta and Pol iota 
together bypassed Pt-GG, suggesting a link between the two proteins. The functions of 
Pol kappa, Pol iota and Pol eta in cells were not mutually exclusive; they could bypass 
the same type of DNA lesions such as Pt-GG and could potentially interact when carrying 
out translesion synthesis in mammalian cells. 
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4.6 Other applications of the high-throughput TLS assay  
The high-throughput TLS assay is a very useful method to determine the mutation rate 
and the mutation spectrum of a DNA lesion in mammalian cells. The assay can be 
conveniently adapted to test many DNA lesions in a few cell lines to pinpoint those 
lesions that have the most mutagenic effects for further study. Researchers can choose to 
use different cell types and change the sequence of the gap region of double stranded gap 
plasmids in their experiments.  
The high-throughput TLS assay can also be used to study the long-term effect of a DNA 
lesion. A time-series study can be carried out to monitor changes in the mutation 
frequency of a DNA lesion and changes in the mutation spectrum of the gap region of the 
double stranded gap plasmids over the course of hours or days in mammalian cells. 
 
4.7 A problem with using E. coli in the traditional TLS assay  
The traditional TLS assay is not a quantitative method to study mutations made by DNA 
lesions precisely because the method uses E.coli. The mutation frequency of a DNA 
lesion observed after bacterial cells have grown overnight does not reflect the mutation 
frequency of the lesion at the time of bacterial transformation.  
To reconcile the results obtained from the traditional TLS assay and those obtained from 
the high-throughput TLS assay, we must understand the difference in dynamics of using 
E. coli versus PCR to amplify DNA. In both cases, the number of DNA sequences 
increases exponentially, but a PCR reaction is a more stable and predictable system than 
the bacterial cell. DNA amplification in PCR reactions is only limited by the 
concentration of DNA templates and the number of PCR cycles. The Phusion® High 
Fidelity DNA polymerase used in PCR reaction is assumed to not make any mutations. 
DNA amplification in E. coli on the other hand, is not constant and is under selective 
pressure—reflected by the change in growth rate of bacteria that may have a qualitative 
effect on producing additional mutations from the one caused by DNA lesion. The 
mutation rate of a DNA lesion conveys an impression of a linear relationship between 
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mutations and the number of nucleotides replicated. Accumulation of mutations in 
bacteria, however, is nonlinear and is subject to influences of bacteria’s growth 
conditions that change with environment. Mutations observed in bacteria due to a DNA 
lesion are results of a series of events starting with translesion synthesis and those 
observed in mammalian cells are results of translesion synthesis only. Difference in time 
produced different observations of mutations that arise from a single DNA lesion.  
 
4.8 Accumulation of mutation is related to the cell's growth 
condition 
My study stumbles upon seeing mutations at different times, from within one generation 
in mammalian cells—as in a still photograph, to across many generations in bacterial 
cells—as in a time-lapsed photograph. The high-throughput TLS assay captures 
mutations caused by a DNA lesion in the short term—the time frame is seven hours in 
cells that double every 24 hours. The traditional TLS assay captures mutations caused by 
a DNA lesion in the long term—the time frame is 16 hours in bacterial cells that double 
every 20 minutes. In the high-throughput assay, we saw only mutation directly opposite 
to the DNA lesion; in the traditional assay, however, we saw accumulation of mutations 
at positions adjacent to the DNA lesion (Appendix C). The difference in results of the 
two methods suggests that the long-term effect of a DNA lesion is closely related to the 
cell's growth condition, and that a single mutation caused by a DNA lesion can lead to 
other mutations in the nearby DNA sequence under selective pressure of the cell. 
Observations from the traditional TLS assay are outcomes from a series of events led by 
translesion synthesis of a DNA lesion.  
 
4.9 Significance of translesion synthesis in survival 
The long-term effects of a DNA lesion in mammalian cells after they have divided many 
times may come to resemble the mutation spectrums observed in bacteria, with increased 
likelihood of mutations for nucleotides adjacent to the DNA lesion. This would be the 
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case especially if the growth condition of mammalian cells is limiting, such as under cell 
culture environment.   
In bacteria, a DNA lesion may have long been removed from DNA sequence as cells 
continue to divide, but the effect of the DNA lesion, such as mutations resulting 
immediately from the lesion can quickly lead to other changes in its surrounding 
nucleotides. Cells have DNA repairs and other mechanisms to maintain the genome's 
equilibrium so mutations cannot increase uncontrollably without qualitative changes in 
the cell.  
Cultured mammalian cells share the same growth dynamic as cultured bacterial cells, but 
an important distinction is that mammalian cells divide every 24 hours instead of every 
20 minutes so mutations in mammalian cells accumulate much more slowly. Mammalian 
cells have more stable dynamics than bacterial cells due to their slower growth rates. This 
implies that properties of mammalian cells change less than those of bacteria in the long 
term and that mammalian cells can better resist changes to DNA sequence arising from a 
DNA lesion. To further explain, it would be much harder for translesion synthesis to 
cause mutations in nucleotides adjacent to DNA lesions in mammalian cells unless there 
are also qualitative changes that speed up the cells’ growth rates. The longer time it takes 
for mammalian cells to divide also leaves more chance for DNA repairs to remove a 
DNA lesion before it is replicated. I argue that mutations resulting from DNA lesions 
observed in bacteria forecast those that will be seen in malignantly transformed 
mammalian cells with uncontrolled growth rate.   
Studying translesion synthesis is looking at a very fundamental level how mutations arise 
spontaneously in response to the environment. Accumulation of mutation is closely 
linked to the cell's growth condition. While the high-throughput TLS assay is useful for 
determining the mutation frequency and the mutation spectrum of a DNA lesion resulting 
immediately from translesion synthesis in the mammalian cell, the traditional TLS assay 
is useful for determining the long-term effect of the lesion in causing additional changes 
to a DNA sequence.  
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The genome is constantly under pressure from DNA lesions and translesion synthesis to 
change its information content. There is an element of chance in where changes in DNA 
sequences would occur. Though translesion synthesis causes subtle variations in the 
genome and is thus easily dismissed, small changes in initial conditions can have far-
reaching consequences. DNA lesions and translesion synthesis are potent driving forces 
of evolution, and similar to Lorenz's butterfly effect (Lorenz, E.N., 1972) small 
perturbations occurring by chance in the sequence of the genome can, over a long time, 
have a large effect in determining the cell’s fate.  
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Appendix A   Effects of translesion DNA polymerases in the 8-
oxo-G study 
Table A-1  Findings from the control plasmids about the frequency of C->A 
substitution across from a regular G nucleotide 
 Analyzed from reads sequenced in 
the FORWARD direction 
 
Analyzed from reads sequenced in 
the REVERSE direction  
Genotypes of the MEF 
cell lines compared 
(N= 9 groups) 
 
Adj. 
P-value 
Cohen’s 
d 
95% C. I. 
Adj.  
P-value 
Cohen’s 
d 
95% C. I. 
POLI(-/-) versus  
POLK(-/-) POLI(-/-) DKO 
 
0.0029 -2.46 -3.9 to -1.02 0.027 -1.6 -2.83 to -0.36 
POLK wild type versus 
POLK(-/-) POLI(-/-) DKO 
 
0.0024 -2.11 -3.47 to -0.76 0.0015 -21.32 -29.86 to -
12.78 
POLK(-/-) versus  
POLK(-/-) POLI(-/-) DKO 
 
0.0024 -2.59 -4.06 to -1.11 0.0015 -3.15 -4.79 to -1.51 
POLK(-/-) versus 2091 
POLI/H/K TKO 
 
0.0143 -2.34 -3.75 to -0.93 0.0015 -2.96 -4.54 to -1.37 
POLK(-/-) versus 2095 
POLI/H/K TKO 
 
0.023 -1.97 -3.3 to -0.65 0.0054 -2.36 -3.78 to -0.94 
Table A-2  Findings from the lesion plasmids about the frequency of C->A 
substitution across from 8-oxo-G 
 Analyzed from reads sequenced in 
the FORWARD direction 
 
Analyzed from reads sequenced in 
the REVERSE direction  
Genotypes of the MEF 
cell lines compared 
(N=9 groups) 
 
Adj. 
P-value 
Cohen’s 
d 
95% C. I. 
Adj.  
P-value 
Cohen’s 
d 
95% C. I. 
REV3L(+/+) P53(-/-) vs. 
REV3L(-/-) P53(-/-)  
Nick name:  
B2 vs. B4(-)18 
 
0.023 -2.05 -3.38 to -0.71 0.015 -1.87 -3.16 to -0.57 
POLH wild type versus 
POLH(-/-)  
 
0.0024 -2.97 -4.56 to -1.39 0.0026 -3.03 -4.63 to -1.42 
POLH wild type versus 
POLH(-/-) POLI(-/-) DKO 
 
0.023 -2.16 -3.53 to -0.80 0.027 -2.07 -3.42 to -0.73 
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Appendix B   Effects of translesion DNA polymerases in the Pt-
GG study 
Translesion DNA polymerases did not make any mutations in the control plasmids. 
Table B-1  Effects of translesion DNA polymerases on causing CC->AC substitution 
across from Pt-GG 
 Analyzed from reads sequenced in 
the FORWARD direction 
 
Analyzed from reads sequenced in 
the REVERSE direction  
Genotypes of the MEF 
cell lines compared  
(N=9 groups) 
 
Adj. 
P-value 
Cohen’s 
d 
95% C. I. 
Adj.  
P-value 
Cohen’s 
d 
95% C. I. 
REV1 wild type vs. 
REV1(-/-) 
 
0.0024 3.17 1.53-4.82 0.0041 3.22 1.56-4.88 
REV3L(+/+) vs.  
REV3L(-/Δ)  
Nickname: 3(+)6 vs. 4(-)5 
 
0.0018 4.65 2.52-6.79 0.0041 4.86 2.66-7.06 
REV3L(+/+) vs.  
REV3L(-/Δ)  
Nickname: 
3(+)6 vs. 4(-)11 
 
0.0018 5.45 3.04-7.87 0.0041 5.12 2.82-7.42 
REV3L(+/+) P53(-/-) vs. 
REV3L(-/-) P53(-/-)  
Nick name:  
B2 vs. B4(-)18 
 
0.015 2.17 0.81-3.54 0.037 1.79 0.51-3.06 
REV3L(+/+) P53(-/-) vs. 
REV3L(-/-) P53(-/-)  
Nick name:  
B2 vs. B4(-)18 
 
0.0018 3.49 1.75-5.24 0.0041 2.92 1.35-4.49 
POLI wild type vs. 
POLK(-/-) POLI(-/-) DKO 
 
0.0024 2.81 1.27-4.35 0.0097 2.64 1.15-4.13 
POLI(-/-) vs.  
POLK(-/-) POLI(-/-) DKO 
 
0.006 2.49 1.04-3.94 0.016 2.45 1.01-3.9 
POLI(-/-) vs.  
2091 POLI(-/-) POLK(-/-) 
POLH(-/-) TKO 
 
0.029 1.86 0.57-3.15 0.042 1.97 0.65-3.28 
POLI(-/-) vs.  
2095 POLI(-/-) POLK(-/-) 
POLH(-/-) TKO 
 
0.0024 3.08 1.46-4.69 0.0041 3.31 1.62-5.0 
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Table B- continues 
Analyzed from reads sequenced in 
the FORWARD direction 
 
Analyzed from reads sequenced in 
the REVERSE direction  
Genotypes of the MEF 
cell lines compared (N=9 
groups) 
Adj. 
P-value 
Cohen’s 
d 
95% C. I. 
Adj.  
P-value 
Cohen’s 
d 
95% C. I. 
POLH wild type vs. 
POLH(-/-) POLI(-/-) DKO 
 
0.038 1.7 0.44-2.95 0.049 1.76 0.49-3.03 
POLH(-/-) vs.  
2091 POLI(-/-) POLK(-/-) 
POLH(-/-) TKO 
 
0.0024 2.32 0.92-3.73 0.0041 2.36 0.95-3.78 
POLH(-/-) vs.  
2095 POLI(-/-) POLK(-/-) 
POLH(-/-) TKO 
 
0.0018 3.48 1.74-5.22 0.0041 3.59 1.81-5.37 
POLK wild type vs. 
POLK(-/-) POLI(-/-) DKO 
 
0.0024 2.95 1.37-4.54 0.0041 2.96 1.37-4.54 
POLK(-/-) vs.  
POLK(-/-) POLI(-/-) DKO 
 
0.01 2.28 0.88-3.67 0.042 1.96 0.64-3.28 
POLK(-/-) vs.  
2095 POLI(-/-) POLK(-/-) 
POLH(-/-) TKO 
 
0.004 2.98 1.39-4.57 0.0041 3.93 2.04-5.81 
POLH(-/-) POLI(-/-) DKO 
vs.  
2091 POLI(-/-) POLK(-/-) 
POLH(-/-) TKO 
 
0.022 1.71 0.45-2.96 0.06 1.48 0.27-2.69 
POLH(-/-) POLI(-/-) DKO 
vs.  
2095 POLI(-/-) POLK(-/-) 
POLH(-/-) TKO 
 
0.0024 3.17 1.52-4.81 0.0041 2.86 1.31-4.42 
 
Table B-2  Effect of Rev3L on causing CC->TC substitution across from Pt-GG 
 Analyzed from reads sequenced in 
the FORWARD direction 
 
Analyzed from reads sequenced in 
the REVERSE direction  
Genotypes of the MEF 
cell lines compared 
(N=9 groups) 
 
Adj. 
P-value 
Cohen’s 
d 
95% C. I. 
Adj.  
P-value 
Cohen’s 
d 
95% C. I. 
REV3L(+/+) P53(-/-) vs. 
REV3L(-/-) P53(-/-)  
Nick name:  
B2 vs. B4(-)18 
 
0.0018 2.28 0.88-3.67 0.049 1.64 0.4-2.89 
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Table B-3  Effect of knocking out both Pol kappa and Pol iota on causing CC->AA 
substitution across Pt-GG 
 Analyzed from reads sequenced in 
the FORWARD direction 
 
Analyzed from reads sequenced in 
the REVERSE direction  
Genotypes of the MEF 
cell lines compared 
(N=9 groups) 
 
Adj. 
P-value 
Cohen’s 
d 
95% C. I. 
Adj.  
P-value 
Cohen’s 
d 
95% C. I. 
POLK wild type vs. 
POLK(-/-) POLI(-/-) DKO 
 
0.038 2.13 0.77-3.49 0.042 2.17 0.8-3.53 
POLI wild type vs. 
POLK(-/-) POLI(-/-) DKO 
 
0.0018 2.27 0.88-3.66 0.0041 2.3 0.9-3.71 
 
 
Table B-4  Effect of knocking out Pol eta and Pol iota together on causing CC->AT 
substitution 
 Analyzed from reads sequenced in 
the FORWARD direction 
 
Analyzed from reads sequenced in 
the REVERSE direction  
Genotypes of the MEF 
cell lines compared 
(N=9 groups) 
 
Adj. 
P-value 
Cohen’s 
d 
95% C. I. 
Adj.  
P-value 
Cohen’s 
d 
95% C. I. 
POLH wild type vs. 
POLH(-/-) POLI(-/-) DKO 
0.038 1.85 0.56-3.14 0.042 1.97 0.65-3.28 
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Appendix C   Mutations arising in the gap region of lesion gap  
plasmids from the traditional TLS assay 
 
For the 8-oxo-G lesion 
 
Figure C-1  Mutations in the gap regions of 8-oxo-G lesion plasmids from a pair of 
MEF cell lines 
89 sequences were analyzed for the MEF POLI(+/+) cell line and 85 sequences were 
analyzed for the MEF POLI(-/-) cell line. The gap sequence is flanked by two dashes. 
The direction of gap-filling is from left to right or 5’ to 3’ of the synthesized strand. The 
‘C’ with the highest mutation rate is opposite to 8-oxo-G.  
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Figure C-2  Mutations in the gap regions of 8-oxo-G lesion plasmid from a pair of 
BL2 cell lines 
93 sequences were analyzed for the BL2 POLI(+/+) cell line and 89 sequences were 
analyzed for the BL2 POLI(-/-) cell line. The gap sequence is flanked by two dashes. The 
direction of gap-filling is from left to right or 5’ to 3’ of the synthesized strand. The ‘C’ 
with the highest mutation rate is opposite to 8-oxo-G. 
 
Table C-1 Numbers of reads with mutations in the gap region of 8-oxo-G lesion 
plasmids in a pair of MEF cell lines for the POLI gene and in a pair of BL2 cell lines 
for the POLI gene. The “C” colored in red is across from the 8-oxo-G lesion. The 12-
nucleotide gap region is highlighted in yellow.  
  Sequence context for the 8-oxo-G study  
Cell line Total 
reads 
C C A G G T A G G A C G C A T G C C G G A A T 
MEF  
POLI WT 
89 1   1    2 1  33 4   1 2        
MEF  
POLI(-/-) 
85 1   1       31   1  1       1 
BL2  
POLI WT 
93        3   17 4   4 8    4  4  
BL2 
POLI(-/-) 
89        6 1  24 2   7 9    10    
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For the Pt-GG lesion 
 
 
Figure C-3  Mutations in the gap regions of Pt-GG lesion plasmids from a pair of 
MEF cell lines for studying the effect of Pol iota 
29 sequences for the MEF POLI(+/+) cell line and 24 sequences were analyzed for the 
POLI(-/-) cell line. The gap sequence is flanked by two dashes. The direction of gap-
filling is from left to right of the given sequence or 5’ to 3’ of the synthesized strand. C1 
denotes the first G of Pt-GG bypassed by a DNA polymerase. C2 denotes the second G of 
Pt-GG bypassed. 
 
89 
 
 
Figure C-4  Mutations in the gap region of Pt-GG lesion plasmids for a pair of MEF 
cell lines for studying the effect of Pol iota.  
29 sequences were analyzed for the MEF POLH(+/+) cell line and 28 sequences were 
analyzed for the MEF POLH(-/-) cell line. The gap sequence is flanked by two dashes. 
The direction of gap-filling is from left to right of the given sequence or 5’ to 3’ of the 
synthesized strand. C1 denotes the first G of Pt-GG bypassed by a DNA polymerase. C2 
denotes the second G of Pt-GG bypassed.  
 
Table C-2  Numbers of reads with mutations in the gap region of Pt-GG lesion 
plasmids in a pair of MEF cell lines for the POLI gene and in a pair of MEF cell 
lines for the POLH gene. The “CC” colored in red is across from the Pt-GG lesion 
with C1 denoting the first insertion step and C2 denoting the second insertion step to 
the lesion. The 12 nucleotide gap region is highlighted in yellow.  
  Sequence context for the Pt-GG study  
Cell line Total 
reads 
C C A G G G C1 C2 A G A G G A A G C C G G A A T 
MEF  
POLI WT 
29       5 2 4         1      
MEF  
POLI (-/-) 
24       4  1 2  1  1          
MEF  
POLH WT 
29  1    1 2 2 1 2  1            
MEF 
POLH(-/-) 
28     1 1 8 2 2 2 1 1       1     
 
90 
 
 
Figure C-5 Mutation spectrums of the gap region of the Pt-GG lesion plasmids in a 
pair of MEF cell lines for the POLI gene.  
C1 and C2 denote the first and the second insertion step to the Pt-GG lesion. The gap 
region of the lesion plasmid is highlighted in yellow. Each symbol above and below the 
sequence shown in black is one observation of the mutation. Δ is deletion.  
 
 
Figure C-6 Mutation spectrums of the gap region of the Pt-GG lesion plasmids in a 
pair of MEF cell lines for the POLH gene.  
C1 and C2 denote the first and the second insertion step to the Pt-GG lesion. The gap 
region of the lesion plasmid is highlighted in yellow. Each symbol above and below the 
sequence shown in black is one observation of the mutation. Δ is deletion. “AC” with the 
same shading appears in the same sequence. 
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Appendix D    Summary statistics of the MiSeq run 
 
Table D-1  Summary statistics of the bi-directional 150 bp MiSeq run 
 Cycles Yield Yield Perfect Yield <=3 errors % Aligned to PhiX 
Read 1 150 2.8 gigabase 258.0 M 305.6M 10.95 
Read 2 150 2.8 gigabase 231.8 M 293.7M 10.74 
Total 300 5.6 gigabase 489.8 M 599.2 M 10.84 
 
 % Perfect 
[num usable cycles] 
Error 
rate1 (%) 
Intensity 
Cycle 
% Intensity 
Cycle 20 
% >= Q30 2 
Read 1 83.3 [149] 0.29 139 20.3 97.5 
Read 2 76.3 [149] 0.48 120 18.0 96.0 
Total 79.8 0.39 129 19.1 96.8 
Note 1: The error rate was determined from a spiked-in PhiX control sample.  
Note 2: Q score, also known as the Phred score was calculated as , where P 
is the error probability. A Q score of 30 means that there is one mistake per every 
thousand nucleotides sequenced.  
 
 
Figure D-1  Q score distributions of the MiSeq run 
(A) By total reads. (B) By cycle. 96.8% of 5.5 gigabases have Q-scores equal to or 
greater than 30.  
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Appendix  E    Isogenic cell lines compared when deducing 
effects of translesion DNA polymerases on 
bypassing 8-oxo-G or Pt-GG  
Table E-1  A list of all the isogenic cell lines that were compared  
Each cell line was used to set up nine transfection experiments or nine biological 
replicates for the study of 8-oxo-G and Pt-GG lesions (Appendices G and J). For each 
pair of cell lines, comparisons were made for the control plasmids and for the lesion 
plasmids, respectively. 
Effect of the 
translesion DNA 
polymerase(s) 
being deduced 
Genotypes of the cell lines compared 
(each cell line has nine biological replicates) 
Cell line  
(with the gene of the DNA 
polymerase in question) 
Cell line  
(deficient for the gene of the DNA 
polymerase in question) 
Pol iota 
 
MEF POLI(+/+)  MEF POL(-/-)  
BL2 POLI(+/+) BL2 POLI(-/-) 
Pol eta MEF POLH(+/+) MEF POLH(-/-)  
MEF POLK(-/-) POLI(-/-) 2091 POLH(-/-) POLI(-/-) POLK(-/-) 
MEF POLK(-/-) POLI(-/-) 2095 POLH(-/-) POLI(-/-) POLK(-/-) 
Pol kappa MEF POLK(+/+) MEF POLK(-/-) 
MEF POLH(-/-) POLI(-/-) 2091 POLH(-/-) POLI(-/-) POLK(-/-) 
MEF POLH(-/-) POLI(-/-) 2095 POLH(-/-) POLI(-/-) POLK(-/-) 
Rev1 MEF REV1(+/+) MEF REV1(-/-) 
Rev3 
 
MEF REV3L(+/+) P53(-/-) 
or B2  
MEF REV3L(-/-) P53(-/-) 
or B4(-)9 
MEF REV3L(+/+) P53(-/-) 
or B2  
MEF REV3L(-/-) P53(-/-) 
or B4(-)18 
MEF REV3L(+/lox) Cre 
or 3(+)6 
MEF REV3L(-/lox) Cre 
or 4(-)5 
MEF REV3L(+/lox) Cre 
or 3(+)6 
MEF REV3L(-/lox) Cre 
or 4(-)11 
Pol iota and  
Pol eta 
MEF POLI(+/+) MEF POLH(-/-) POLI(-/-) 
MEF POLH(+/+) MEF POLH(-/-) POLI(-/-)  
MEF POLK(-/-) 2091 POLH(-/-) POLI(-/-) POLK(-/-) 
MEF POLK(-/-) 2095 POLH(-/-) POLI(-/-) POLK(-/-) 
Pol iota and  
Pol kappa 
MEF POLI(+/+) MEF POLI(-/-) POLK(-/-) 
MEF POLK(+/+) MEF POLI(-/-) POLK(-/-)  
MEF POLH(-/-) 2091 POLH(-/-) POLI(-/-) POLK(-/-) 
MEF POLH(-/-) 2095 POLH(-/-) POLI(-/-) POLK(-/-) 
Pol eta and  
Pol kappa 
MEF POLI(-/-) 2091 POLH(-/-) POLI(-/-) POLK(-/-) 
MEF POLI(-/-) 2095 POLH(-/-) POLI(-/-) POLK(-/-) 
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Appendix F No. of reads for DNA samples in the 8-oxo-G study 
Transfection 
Experiment 
Total 
Reads 
Reads of 
Control 
Plasmids 
Reads of 
Lesion 
Plasmids 
 
Transfection 
Experiment 
Total 
Reads 
Reads of 
Control 
Plasmids 
Reads of 
Lesion 
Plasmids 
L1R1 5193 3394 1799  L2R1 4229 2767 1462 
L1R2 5523 3485 2038  L2R2 6307 3982 2325 
L1R3 4881 3121 1760  L2R3 6257 3954 2303 
L1R4 4938 3161 1777  L2R4 7310 4648 2662 
L1R5 4441 2854 1587  L2R5 10006 6828 3178 
L1R6 3722 2382 1340  L2R6 6933 4394 2539 
L1R7 4963 3086 1877  L2R7 6245 3877 2368 
L1R8 5413 3392 2021  L2R8 5365 3370 1995 
L1R9 4619 2994 1625  L2R9 4736 3137 1599 
L1R10 5820 3490 2330  L2R10 5485 3504 1981 
L1R11 4724 3046 1678  L2R11 4675 3020 1655 
L1R12 4256 2735 1521  L2R12 6966 4298 2668 
L1R13 5626 3538 2088  L2R13 7147 4401 2746 
L1R14 4451 2822 1629  L2R14 6961 4332 2629 
L1R15 4418 2786 1632  L2R15 4672 2927 1745 
L1R16 5236 3332 1904  L2R16 6050 3809 2241 
L1R17 6182 3936 2246  L2R17 7911 5009 2902 
L1R18 6631 4137 2494  L2R18 7432 4782 2650 
L1R19 9834 6870 2964  L2R19 5998 3858 2140 
L1R20 4456 2820 1636  L2R20 5008 3221 1787 
L1R21 4446 2824 1622  L2R21 8145 5177 2968 
L1R22 4543 2932 1611  L2R22 3894 2625 1269 
L1R23 4770 3032 1738  L2R23 7058 4571 2487 
L1R24 4439 2811 1628  L2R24 7232 4569 2663 
         
Transfection 
Experiment 
Total 
Reads 
Reads of 
Control 
Plasmids 
Reads of 
Lesion 
Plasmids 
 
Transfection 
Experiment 
Total 
Reads 
Reads of 
Control 
Plasmids 
Reads of 
Lesion 
Plasmids 
L3R1 5280 3366 1914  L4R1 5567 3442 2125 
L3R2 5888 3750 2138  L4R2 5355 3410 1945 
L3R3 5577 3500 2077  L4R3 6128 3795 2333 
L3R4 5392 3378 2014  L4R4 6345 4000 2345 
L3R5 3687 2361 1326  L4R5 8271 5220 3051 
L3R6 3656 2376 1280  L4R6 7694 5142 2552 
L3R7 3592 2314 1278  L4R7 6325 4051 2274 
L3R8 4043 2584 1459  L4R8 7357 4734 2623 
L3R9 3740 2543 1197  L4R9 7111 4623 2488 
L3R10 3680 2447 1233  L4R10 6945 4442 2503 
L3R11 4387 2992 1395  L4R11 7669 4920 2749 
L3R12 3997 2767 1230  L4R12 8223 5000 3223 
L3R13 3974 2667 1307  L4R13 7401 4459 2942 
L3R14 4160 2816 1344  L4R14 8379 5170 3209 
L3R15 3915 2403 1512  L4R15 6419 4017 2402 
L3R16 4949 3107 1842  L4R16 6199 3934 2265 
94 
 
Transfection 
Experiment 
Total 
Reads 
Reads of 
Control 
Plasmids 
Reads of 
Lesion 
Plasmids 
 
Transfection 
Experiment 
Total 
Reads 
Reads of 
Control 
Plasmids 
Reads of 
Lesion 
Plasmids 
L3R17 4010 2522 1488  L4R17 9094 5758 3336 
L3R18 4354 2784 1570  L4R18 4918 3027 1891 
L3R19 4610 2958 1652  L4R19 7306 4534 2772 
L3R20 4327 2667 1660  L4R20 6398 4051 2347 
L3R21 4031 2547 1484  L4R21 8753 5605 3148 
L3R22 3548 2260 1288  L4R22 7910 5026 2884 
L3R23 3821 2378 1443  L4R23 8483 5463 3020 
L3R24 3995 2493 1502  L4R24 6358 4013 2345 
         
Transfection 
Experiment 
Total 
Reads 
Reads of 
Control 
Plasmids 
Reads of 
Lesion 
Plasmids 
 
Transfection 
Experiment 
Total 
Reads 
Reads of 
Control 
Plasmids 
Reads of 
Lesion 
Plasmids 
L5R1 7351 4998 2353  L6R1 10167 6464 3703 
L5R2 8251 5682 2569  L6R2 14701 9212 5489 
L5R3 7224 4420 2804  L6R3 10725 6556 4169 
L5R4 9021 5513 3508  L6R4 12411 7734 4677 
L5R5 7985 4954 3031  L6R5 12677 7970 4707 
L5R6 7033 4497 2536  L6R6 12833 7822 5011 
L5R7 9087 5648 3439  L6R7 13942 8520 5422 
L5R8 7589 4745 2844  L6R8 13615 8249 5366 
L5R9 8477 5594 2883  L6R9 12618 8989 3629 
L5R10 7374 4816 2558  L6R10 10513 7405 3108 
L5R11 10736 7024 3712  L6R11 14519 10347 4172 
L5R12 8844 5689 3155  L6R12 11808 7271 4537 
L5R13 9324 5913 3411  L6R13 11314 6809 4505 
L5R14 9991 6476 3515  L6R14 12280 7137 5143 
L5R15 5919 3739 2180  L6R15 14372 9002 5370 
L5R16 10110 6401 3709  L6R16 11779 7439 4340 
L5R17 7882 6912 970  L6R17 13535 8581 4954 
L5R18 7006 4505 2501  L6R18 12023 7359 4664 
L5R19 7136 4722 2414  L6R19 13418 8231 5187 
L5R20 6720 4344 2376  L6R20 10946 6750 4196 
L5R21 9912 6279 3633  L6R21 15456 9860 5596 
L5R22 10269 6376 3893  L6R22 12554 8020 4534 
L5R23 9522 5901 3621  L6R23 11146 7134 4012 
L5R24 9009 5856 3153  L6R24 14447 9048 5399 
         
Transfection 
Experiment 
Total 
Reads 
Reads of 
Control 
Plasmids 
Reads of 
Lesion 
Plasmids 
 
Transfection 
Experiment 
Total 
Reads 
Reads of 
Control 
Plasmids 
Reads of 
Lesion 
Plasmids 
L7R1 12256 7607 4649  L22R1 5312 3437 1875 
L7R2 12487 7794 4693  L22R2 6086 3844 2242 
L7R3 11907 7548 4359  L22R3 6395 4053 2342 
L7R4 11752 7557 4195  L22R4 5998 3822 2176 
L7R5 11474 7306 4168  L22R5 6670 4260 2410 
L7R6 12120 7797 4323  L22R6 6360 3992 2368 
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Total 
Reads 
Reads of 
Control 
Plasmids 
Reads of 
Lesion 
Plasmids 
 
 
Total 
Reads 
Reads of 
Control 
Plasmids 
Reads of 
Lesion 
Plasmids 
L7R7 9487 5913 3574  L22R7 6808 4340 2468 
L7R8 13455 8305 5150  L22R8 5962 3874 2088 
L7R9 13440 8535 4905  L22R9 6888 4372 2516 
L7R10 11052 6926 4126  L22R10 6118 3948 2170 
L7R11 12217 7663 4554  L22R11 6427 4047 2380 
L7R12 12457 7756 4701  L22R12 7113 4330 2783 
L7R13 19743 12271 7472  L22R13 7428 4489 2939 
L7R14 13451 8474 4977  L22R14 8403 5204 3199 
L7R15 12535 7849 4686  L22R15 1535 1058 477 
L7R16 12181 7568 4613  L22R16 1700 1191 509 
L7R17 12666 8063 4603  L22R17 4440 3932 508 
L7R18 15353 9618 5735  L22R18 4322 3841 481 
L7R19 5311 3378 1933  L22R19 4087 3605 482 
L7R20 5174 3359 1815  L22R20 1419 996 423 
L7R21 5684 3694 1990  L22R21 1628 1120 508 
L7R22 5236 3390 1846  L22R22 1415 991 424 
L7R23 5091 3320 1771  L22R23 1367 960 407 
L7R24 6371 4144 2227  L22R24 1602 1144 458 
Note:  
L22R15 and L22R16 are no DNA negative PCR controls whereby no DNA was added in 
PCR reactions.  
L22R17, L22R18 and L22R19 are positive PCR controls whereby intact double stranded 
control plasmids were added in PCR reactions for determining experimental errors.  
L22R20, L22R21 and L22R22 are negative controls for transfection whereby control gap 
plasmids were added to MEF cells without transfection reagent. 
L22R23 and L22R24 are negative controls for transfection whereby control gap plasmids 
were added to BL2 cells without transfection reagent.  
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Appendix G    Cell lines used for transfection experiments in 
the 8-oxo-G study 
 
Cell line Transfection experiments 
MEF POLI(+/+) L1R1 to L1R9 
MEF POLI(-/-) L1R10 to L1R18 
BL2 POLI(+/+) L1R19 to L1R24, L2R1 to L2R4 
BL2 POLI(-/-) L2R5 to L2R14 
MEF POLH(+/+) L2R15 to L2R23 
MEF POLH(-/-) L2R24, L3R1 to L3R8 
MEF POLK(+/+) L3R9 to L3R17 
MEF POLK(-/-) L3R18 to L3R24, L4R1, L4R2 
MEF REV1(+/+) L4R3 to L4R11 
MEF REV1(-/-) L4R12 to L4R20 
MEF POLH(-/-) POLI(-/-) L4R21 to L4R24, L5R1 to L5R5 
MEF POLH(-/-) POLI(-/-) POLK(-/-), 2091 L5R6 to L5R14 
MEF POLH(-/-) POLI(-/-) POLK(-/-), 2095 L5R15 to L5R23 
MEF POLK(-/-) POLI(-/-), 2092 L5R24, L6R1 to L6R8 
MEF REV3L(+/Δ), nickname: 3(+)6 L6R9 to L6R17 
MEF REV3L(-/Δ), nickname: 4(-)5 L6R18 to L6R24, L7R1, L7R2 
MEF REV3L(-/Δ), nickname: 4(-)11 L7R3 to L7R11 
MEF REV3L(+/+), P53(-/-), nickname: B2 L7R12 to L7R20 
MEF REV3L(+/+), P53(-/-), nickname: B4-9 L7R21 to L7R24, L22R1 to L22R5 
MEF REV3L(+/+), P53(-/-), nickname: B4-18 L22R6 to L22R14 
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Appendix H    Mutation frequencies of control plasmids and 
lesion plasmids in the 8-oxo-G study for each cell 
line 
Cell line 
Average mutation 
frequency across from a 
regular G in control 
plasmids (N=9 samples) 
Average mutation 
frequency across from an 
8-oxo-G in lesion plasmids 
(N=9 samples) 
MEF POLI(+/+) 0.019265±0.003387 0.901709±0.020447 
MEF POLI(-/-) 0.013826±0.002641 0.921682±0.025595 
BL2 POLI(+/+) 0.010293±0.007336 0.918242±0.043828 
BL2 POLI(-/-) 0.015254±0.005925 0.903451±0.031048 
MEF POLH(+/+) 0.012623±0.004703 0.868926±0.029094 
MEF POLH(-/-) 0.014634±0.006322 0.929683±0.010711 
MEF POLK(+/+) 0.008282±0.003878 0.927235±0.024269 
MEF POLK(-/-) 0.007575±0.005674 0.932431±0.014121 
MEF POLH(-/-) POLI(-/-) 0.018589±0.005959 0.919158±0.016402 
MEF POLH(-/-) POLI(-/-) 
POLK(-/-), 2091 
0.023589±0.004759 0.913149±0.004392 
MEF POLH(-/-) POLI(-/-) 
POLK(-/-), 2095 
0.018639±0.002599 0.919177±0.015477 
MEF POLK(-/-) POLI(-/-), 
2092 
0.01898±0.006801 0.931155±0.009086 
MEF REV1(+/+) 0.019328±0.005146 0.906739±0.011112 
MEF REV1(-/-) 0.01682±0.00477 0.914846±0.011736 
MEF REV3L(+/Δ), 
nickname: 3(+)6 
0.020843±0.003397 0.885401±0.020573 
MEF REV3L(-/Δ), 
nickname: 4(-)5 
0.019108±0.001546 0.908886±0.009407 
MEF REV3L(-/Δ), 
nickname: 4(-)11 
0.020931±0.004855 0.906337±0.007816 
MEF REV3L(+/+), P53(-/-), 
nickname: B2 
0.025063±0.008512 0.896716±0.020351 
MEF REV3L(+/+), P53(-/-), 
nickname: B4-9 
0.025855±0.01121 0.897937±0.03203 
MEF REV3L(+/+), P53(-/-), 
nickname: B4-18 
0.016891±0.005043 0.926601±0.011012 
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Appendix  I  No. of reads for DNA samples in the Pt-GG study 
Transfection 
Experiment 
Total 
Reads 
Reads of 
Control 
Plasmids 
Reads of 
Lesion 
Plasmids 
 
Transfection 
Experiment 
Total 
Reads 
Reads of 
Control 
Plasmids 
Reads of 
Lesion 
Plasmids 
L8L15R1 36024 17863 18161  L9L16R1 64482 37988 26494 
L8L15R2 36207 18928 17279  L9L16R2 67825 37640 30185 
L8L15R3 35457 19361 16096  L9L16R3 68797 39394 29403 
L8L15R4 40351 20797 19554  L9L16R4 65804 37270 28534 
L8L15R5 40306 19659 20647  L9L16R5 68370 37120 31250 
L8L15R6 41563 23831 17732  L9L16R6 74466 44853 29613 
L8L15R7 46500 26165 20335  L9L16R7 71140 41356 29784 
L8L15R8 44003 25446 18557  L9L16R8 76563 46366 30197 
L8L15R9 51500 28085 23415  L9L16R9 65740 36375 29365 
L8L15R10 42392 28024 14368  L9L16R10 68844 40462 28382 
L8L15R11 55695 30419 25276  L9L16R11 82529 49950 32579 
L8L15R12 53285 30590 22695  L9L16R12 71837 39618 32219 
L8L15R13 54559 29274 25285  L9L16R13 81171 47970 33201 
L8L15R14 53104 30179 22925  L9L16R14 70830 40003 30827 
L8L15R15 48927 29555 19372  L9L16R15 62436 35253 27183 
L8L15R16 55594 32009 23585  L9L16R16 71543 43289 28254 
L8L15R17 58006 34832 23174  L9L16R17 71266 41221 30045 
L8L15R18 60290 39704 20586  L9L16R18 77326 47557 29769 
L8L15R19 51834 26436 25398  L9L16R19 75568 43406 32162 
L8L15R20 64230 44079 20151  L9L16R20 67533 40635 26898 
L8L15R21 63154 42904 20250  L9L16R21 74950 41790 33160 
L8L15R22 46743 29133 17610  L9L16R22 68953 40884 28069 
L8L15R23 51651 25681 25970  L9L16R23 69949 37927 32022 
L8L15R24 57671 34374 23297  L9L16R24 70154 39769 30385 
         
Transfection 
Experiment 
Total 
Reads 
Reads of 
Control 
Plasmids 
Reads of 
Lesion 
Plasmids 
 
Transfection 
Experiment 
Total 
Reads 
Reads of 
Control 
Plasmids 
Reads of 
Lesion 
Plasmids 
L10L17R1 56715 41330 15385  L11L18R1 46782 34241 12541 
L10L17R2 78852 55635 23217  L11L18R2 43657 30693 12964 
L10L17R3 66577 38615 27962  L11L18R3 48643 35021 13622 
L10L17R4 66259 39749 26510  L11L18R4 52460 37590 14870 
L10L17R5 40689 19015 21674  L11L18R5 52404 37337 15067 
L10L17R6 42661 20383 22278  L11L18R6 46875 29987 16888 
L10L17R7 47258 17672 29586  L11L18R7 49028 32675 16353 
L10L17R8 52330 21168 31162  L11L18R8 48714 32294 16420 
L10L17R9 54341 21079 33262  L11L18R9 54014 36173 17841 
L10L17R10 52122 20580 31542  L11L18R10 51793 33239 18554 
L10L17R11 58771 25643 33128  L11L18R11 51801 33664 18137 
L10L17R12 55036 24683 30353  L11L18R12 55341 38338 17003 
L10L17R13 59710 27163 32547  L11L18R13 58658 38585 20073 
L10L17R14 54427 22966 31461  L11L18R14 52695 33694 19001 
L10L17R15 52433 23587 28846  L11L18R15 50965 33755 17210 
L10L17R16 59790 26321 33469  L11L18R16 56964 38407 18557 
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Transfection 
Experiment 
Total 
Reads 
Reads of 
Control 
Plasmids 
Reads of 
Lesion 
Plasmids 
 
Transfection 
Experiment 
Total 
Reads 
Reads of 
Control 
Plasmids 
Reads of 
Lesion 
Plasmids 
L10L17R17 53811 27940 25871  L11L18R17 61006 40607 20399 
L10L17R18 57204 26774 30430  L11L18R18 54630 40289 14341 
L10L17R19 57464 27886 29578  L11L18R19 56546 36449 20097 
L10L17R20 50519 24620 25899  L11L18R20 38641 34745 3896 
L10L17R21 58053 27008 31045  L11L18R21 60615 38777 21838 
L10L17R22 52774 23931 28843  L11L18R22 51836 32653 19183 
L10L17R23 41139 26785 14354  L11L18R23 56257 35966 20291 
L10L17R24 39741 25207 14534  L11L18R24 57467 38795 18672 
         
Transfection 
Experiment 
Total 
Reads 
Reads of 
Control 
Plasmids 
Reads of 
Lesion 
Plasmids 
 
Transfection 
Experiment 
Total 
Reads 
Reads of 
Control 
Plasmids 
Reads of 
Lesion 
Plasmids 
L12L19R1 66628 39811 26817  L13L20R1 68368 46307 22061 
L12L19R2 63410 41054 22356  L13L20R2 70656 45948 24708 
L12L19R3 59615 39642 19973  L13L20R3 66731 40607 26124 
L12L19R4 67930 43535 24395  L13L20R4 73834 46485 27349 
L12L19R5 72946 41709 31237  L13L20R5 70185 44272 25913 
L12L19R6 83461 56198 27263  L13L20R6 75937 45527 30410 
L12L19R7 65460 41530 23930  L13L20R7 68043 43317 24726 
L12L19R8 77384 49889 27495  L13L20R8 73955 49054 24901 
L12L19R9 77126 48229 28897  L13L20R9 78625 51148 27477 
L12L19R10 78838 50848 27990  L13L20R10 75918 49228 26690 
L12L19R11 73492 42849 30643  L13L20R11 72757 46242 26515 
L12L19R12 71107 42338 28769  L13L20R12 78867 52278 26589 
L12L19R13 76450 46819 29631  L13L20R13 71363 40508 30855 
L12L19R14 42905 15582 27323  L13L20R14 66372 41795 24577 
L12L19R15 69864 45212 24652  L13L20R15 72626 47232 25394 
L12L19R16 68766 42805 25961  L13L20R16 78395 51335 27060 
L12L19R17 73579 45959 27620  L13L20R17 81469 49601 31868 
L12L19R18 73856 45505 28351  L13L20R18 59811 38608 21203 
L12L19R19 72559 49140 23419  L13L20R19 73654 47798 25856 
L12L19R20 67281 44924 22357  L13L20R20 68656 45474 23182 
L12L19R21 74570 51622 22948  L13L20R21 73762 46316 27446 
L12L19R22 73241 44819 28422  L13L20R22 62216 37289 24927 
L12L19R23 61487 38023 23464  L13L20R23 43166 19251 23915 
L12L19R24 73060 44784 28276  L13L20R24 52392 21890 30502 
         
Transfection 
Experiment 
Total 
Reads 
Reads of 
Control 
Plasmids 
Reads of 
Lesion 
Plasmids 
 
Transfection 
Experiment 
Total 
Reads 
Reads of 
Control 
Plasmids 
Reads of 
Lesion 
Plasmids 
L14L21R1 43780 19325 24455  L23L24R1 62856 49312 13544 
L14L21R2 38717 20072 18645  L23L24R2 55453 42078 13375 
L14L21R3 48448 19932 28516  L23L24R3 65605 50502 15103 
L14L21R4 47107 21231 25876  L23L24R4 64659 49128 15531 
L14L21R5 48792 22446 26346  L23L24R5 51577 44095 7482 
L14L21R6 56677 25800 30877  L23L24R6 76682 56799 19883 
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Transfection 
Experiment 
Total 
Reads 
Reads of 
Control 
Plasmids 
Reads of 
Lesion 
Plasmids 
 
Transfection 
Experiment 
Total 
Reads 
Reads of 
Control 
Plasmids 
Reads of 
Lesion 
Plasmids 
L14L21R7 51910 23832 28078  L23L24R7 70990 56094 14896 
L14L21R8 50361 25094 25267  L23L24R8 68275 52921 15354 
L14L21R9 50758 26100 24658  L23L24R9 69109 52149 16960 
L14L21R10 52261 24623 27638  L23L24R10 62660 45472 17188 
L14L21R11 52510 25159 27351  L23L24R11 64814 47544 17270 
L14L21R12 54589 27700 26889  L23L24R12 69844 51431 18413 
L14L21R13 57830 28064 29766  L23L24R13 35231 29816 5415 
L14L21R14 45336 17483 27853  L23L24R14 16229 10119 6110 
L14L21R15 50429 25363 25066  L23L24R15 32519 28990 3529 
L14L21R16 54078 26037 28041  L23L24R16 70670 45932 24738 
L14L21R17 46502 30175 16327  L23L24R17 71456 52494 18962 
L14L21R18 48119 32340 15779  L23L24R18 71659 47168 24491 
L14L21R19 46204 29511 16693  L23L24R19 45740 40544 5196 
L14L21R20 41429 27453 13976  L23L24R20 30318 26105 4213 
L14L21R21 45934 31675 14259  L23L24R21 35904 31754 4150 
L14L21R22 41911 27266 14645  L23L24R22 49326 38090 11236 
L14L21R23 42233 26767 15466  L23L24R23 31946 26151 5795 
L14L21R24 44787 29171 15616  L23L24R24 44769 34364 10405 
Note:  
L23/L24R13, L23/L24R14 and L23/L24R15 are no DNA negative PCR controls 
whereby no DNA was added in PCR reactions.  
L23R16, L23R17 and L23R18 are positive control PCR reactions whereby intact and 
fully double stranded control plasmids were added in PCR reactions to determine 
experimental errors. Similarly, L24R16, L24R17 and L24R18 are positive control PCR 
reactions whereby intact and fully double stranded lesion plasmids (without Pt-GG 
crosslinks) were added in PCR reactions.  
L23/L24R19, L23/L24R20 and L23/L24R21 are negative control reactions for 
transfection where control and lesion gap plasmid mixtures were added and incubated 
with MEF cells without using transfection reagent.  
Similarly, L23/L24R22, L23/L24R23, L23/L24R24 are negative control reactions for 
transfection where control and lesion gap plasmid mixtures were added and incubated 
with BL2 cells without using transfection reagent.  
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Appendix J     Cell lines used for transfection experiments in 
the Pt-GG study 
 
Cell line Transfection experiments 
MEF POLI(+/+) L8L15R1 to L8L15R9 
MEF POLI(-/-) L8L15R10 to L8L15R18 
BL2 POLI(+/+) 
L8L15R19 to L8L15R24,  
L9L16R1 to L9L16R3 
BL2 POLI(-/-) L9L16R4 to L9L16R12 
MEF POLH(+/+) L9L16R13 to L9L16R21 
MEF POLH(-/-) 
L9L16R22 to L9L16R24, 
L10L17R1 to L10L17R6 
MEF POLK(+/+) L10L17R7 to L10L17R15 
MEF POLK(-/-) L10L17R16 to L10L17R24 
MEF REV1(+/+) L11L18R1 to L11L18R9 
MEF REV1(-/-) L11L18R10 to L11L18R18 
MEF POLH(-/-) POLI(-/-) 
L11L18R19 to L11L18R24 
L12L19R1 to L12L19R3 
MEF POLH(-/-) POLI(-/-) POLK(-/-), 2091 L12L19R4 to L12L19R12 
MEF POLH(-/-) POLI(-/-) POLK(-/-), 2095 L12L19R13 to L12L19R21 
MEF POLK(-/-) POLI(-/-), 2092 
L12L19R22 to L12L19R24 
L13L20R1 to L13L20R6 
MEF REV3L(+/Δ), nickname: 3(+)6 L13L20R7 to L13L20R15 
MEF REV3L(-/Δ), nickname: 4(-)5 L13L20R16 to L13L20R24 
MEF REV3L(-/Δ), nickname: 4(-)11 L14L21R1 to L14L21R9 
MEF REV3L(+/+), P53(-/-), nickname: B2 L14L21R10 to L14L21R18 
MEF REV3L(+/+), P53(-/-), nickname: B4-9 
L14L21R19 to L14R21R24 
L23L24R1 to L23R24R3 
MEF REV3L(+/+), P53(-/-), nickname: B4-18 L23L24R4 to L23L24R12 
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Appendix K  Mutation frequencies of control plasmids and 
lesion plasmids in the Pt-GG study for each cell 
line  
  
Cell lines 
Average mutation frequencies of 
control plasmids across from GG 
(N=9 samples) 
Average mutation frequencies of 
lesion plasmids across from Pt-GG 
(N=9 samples) 
The 1st insertion 
step 
The 2nd insertion 
step 
The 1st insertion 
step 
The 2nd insertion 
step 
MEF 
POLI(+/+) 
0.00633582 
±0.00060603 
0.00211604 
±0.00042729 
0.00797014 
±0.00235359 
0.00325844 
±0.00081405 
MEF  
POLI(-/-) 
0.00623971 
±0.00026943 
0.00210229 
±0.00033156 
0.00676418 
±0.00178312 
0.00335374 
±0.00046932 
BL2 
POLI(+/+) 
0.00672665 
±0.00037447 
0.00211498 
±0.00050253 
0.00357752 
±0.00104655 
0.00274966 
±0.0008659 
BL2  
POLI(-/-) 
0.00697197 
±0.0004663 
0.00213745 
±0.0002034 
0.00453663 
±0.00094203 
0.00373258 
±0.00065256 
MEF 
POLH(+/+) 
0.00671445 
±0.00063946 
0.00213002 
±0.00023077 
0.01264681 
±0.00534483 
0.00498744 
±0.00091888 
MEF  
POLH(-/-) 
0.00659034 
±0.00070424 
0.00223973 
±0.0002914 
0.00967711 
±0.00290917 
0.00426218 
±0.0004818 
MEF 
POLK(+/+) 
0.00631168 
±0.00053691 
0.00197384 
±0.00028981 
0.00817649 
±0.00205302 
0.00405642 
±0.00065313 
MEF  
POLK(-/-) 
0.00647793 
±0.00061005 
0.00205539 
±0.00054222 
0.00692088 
±0.00098325 
0.00403449 
±0.0004382 
MEF  
POLH(-/-) 
POLI(-/-) 
0.00669208 
±0.00032507 
0.00218667 
±0.00035575 
0.00747425 
±0.00113811 
0.0040025 
±0.00033642 
MEF  
POLK(-/-) 
POLI(-/-), 
2092 
0.00651591 
±0.00044 
0.00215294 
±0.00036743 
0.00506356 
±0.0009081 
0.00361153 
±0.00053964 
MEF  
POLH(-/-) 
POLI(-/-) 
POLK(-/-), 
2091 
0.00665362 
±0.00021903 
0.00221712 
±0.00022728 
0.00501292 
±0.00076192 
0.00345792 
±0.00056011 
Table continues in the next page … 
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Appendix K continues … 
Cell line 
Average mutation frequencies of 
control plasmids across from GG 
(N=9 samples) 
Average mutation frequencies of 
lesion plasmids across from Pt-GG 
(N=9 samples) 
The 1st insertion 
step (C1) 
The 2nd insertion 
step (C2) 
The 1st insertion 
step (C1) 
The 2nd insertion 
step (C2) 
MEF  
POLH(-/-) 
POLI(-/-) 
POLK(-/-), 
2095 
0.00657383 
±0.00041924 
0.00227921 
±0.0005008 
0.00409557 
±0.00071602 
0.00307922 
±0.00065915 
MEF 
REV1(+/+) 
0.00685436 
±0.00052085 
0.00213745 
±0.00030857 
0.00756895 
±0.00153204 
0.00431359 
±0.00063232 
MEF  
REV1(-/-) 
0.00652176 
±0.00024146 
0.00214813 
±0.00035795 
0.00435796 
±0.00056597 
0.00338934 
±0.0007335 
MEF 
REV3L(+/Δ), 
3(+)6 
0.00658979 
±0.00043858 
0.00206947 
±0.00023479 
0.01030133 
±0.00235666 
0.00440965 
±0.00076919 
MEF  
REV3L(-/Δ), 
4(-)5 
0.00678478 
±0.00053557 
0.00217725 
±0.00046891 
0.00490431 
±0.00095976 
0.00389058 
±0.00105612 
MEF  
REV3L(-/Δ), 
4(-)11 
0.00678595 
±0.00036631 
0.0020206 
±0.00028687 
0.00413251 
±0.00091898 
0.00370398 
±0.00064044 
MEF 
REV3L(+/+) 
P53(-/-), 
B2 
0.00659605 
±0.00034117 
0.00205079 
±0.00025514 
0.00651752 
±0.00073177 
0.00400263 
±0.00060623 
MEF 
REV3L(+/+) 
P53(-/-), 
B4-9 
0.00665444 
±0.0050896 
0.00217355 
±0.00023279 
0.00498804 
±0.00057864 
0.00395544 
±0.00076486 
MEF 
REV3L(+/+) 
P53(-/-),  
B4-18 
0.00656054 
±0.00034216 
0.00227396 
±0.00027169 
0.00457931 
±0.00109652 
0.00427594 
±0.00105971 
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